Skip to Main Content
Directory of Faculty Research Interests
YSM Home

INFORMATION FOR

DownloadHi-Res Photo

Xavier Llor, MD, PhD

Professor of Medicine; Associate CEHE Director for Cancer Screening, Smilow Cancer Hospital; Medical Director, Cancer Screening and Prevention Program, and Colorectal Cancer Prevention Program; Co-Director, Cancer Genetics and Prevention Program

Contact Information

Xavier Llor, MD, PhD

Mailing Address

  • Yale School of Medicine

    Department of Medicine (Digestive Diseases), PO Box 208019

    New Haven, CT 06520-8019

    United States

Related Links

Yale Medicine

Patient Care

Are you a patient?Please visit the Yale Medicine website for information about the services we offer and making an appointment.View Doctor Profile

Research Summary

Dr. Llor’s research interests relate to colorectal cancer. He focuses his studies on forms of colorectal cancers that can be passed along through the genes and thus can affect multiple members in a family. He is trying to unveil specific genes that can be responsible for some of these cases and how cancers in these families develop. He is also interested in understanding why some racial groups are more prone to develop colorectal cancer than others and how environmental factors can play a key role in colorectal cancer development

Specialized Terms: Mismatch Repair Proficient Hereditary Non-Polyposis Colorectal Cancer; MSS-HNPCC: Lynch syndrome; Colorectal Cancer Disparities: Colorectal Cancer in African Americans

Extensive Research Description

Dr. Llor obtained his MD degree at the Autonomous University of Barcelona and his PhD in molecular biology at the University of Barcelona. He completed his Internal Medicine Residency at the University of Chicago-Lutheran General Hospital Program and his GI fellowship at the University of Illinois at Chicago. In 2014, Dr. Llor joined Yale University as co-Director of the Cancer Genetics and Prevention Program, Medical Director of the Colorectal Cancer Prevention Program, and more recently Associate Director of Cancer Screening at Yale's Cancer Center.

A clinically active gastroenterologist, Dr. Llor's research and clinical interests relate to GI cancer, mostly colorectal and stomach, with an emphasis on genetics and disparities. He spearheaded and carried out three large prospective cohorts of colorectal cancer patients and controls that produced a wealth of information. Some important contributions from Dr. Llor's lab include the description of the best diagnostic approaches to Lynch syndrome diagnosis; clinical and molecular characterization of mismatch repair proficient hereditary non-polyposis colorectal cancer (type X); identification of distinct clinical and molecular features of colorectal cancers in young African Americans, phenotypic features of hereditary gastric cancer.

Some of the themes of my research include:

1. Lynch syndrome (LS) is the most common inherited CRC syndrome and it is characterized by cancer development at a young age and very high risk of different extra-colonic malignancies. Affected family members require intensive cancer surveillance. LS is caused by mutations in the mismatch repair genes that result in tumor microsatellite instability (MSI) and loss of expression of the corresponding protein. A tremendous challenge is still diagnosing individuals with LS as patients do not have an obvious pre-morbid phenotype (development of multiple polyps) that could suggest the presence of this syndrome. Thus, establishing the best diagnostic approaches has been an important priority over the last few years. I have performed several studies that have become seminal in the diagnostic process of LS.

a. Pinol, Castells A, Andreu M, Castellví-Bel S, Alenda C, et al. Accuracy of revised Bethesda guidelines, microsatellite instability, and immunohistochemistry for the identification of patients with hereditary nonpolyposis colorectal cancer. JAMA. 2005 Apr 27;293(16):1986-94.

b. Xicola RM, Llor X*, Pons E, Castells A, Alenda C, et al. Performance of different microsatellite marker panels for detection of mismatch repair-deficient colorectal tumors. J Natl Cancer Inst. 2007 Feb 7;99(3):244-52. *Corresponding author.

c. Balaguer F, Balmaña J, Castellví-Bel S, Steyerberg EW, Andreu M, et al. Validation and extension of the PREMM1,2 model in a population-based cohort of colorectal cancer patients. Gastroenterology. 2008 Jan;134(1):39-46. PMCID: PMC2542581.

d. Bessa X, Ballesté B, Andreu M, Castells A, Bellosillo B, et al. A prospective, multicenter, population-based study of BRAF mutational analysis for Lynch syndrome screening. Clin Gastroenterol Hepatol. 2008 Feb;6(2):206-14.

2. African Americans have the highest incidence and mortality from colorectal cancer and several studies have suggested some clear biological differences. In order to better understand these differences while taking into account social and environmental factors, I established and lead the Chicago Colorectal Cancer Consortium (CCCC), a multiethnic cohort that recruited over 600 patients with CRC of which over 60% are African Americans. The CCCC established a strong team of collaborators working towards the identification of genetic-environmental interactions and socio-economic aspects. Some important findings have already been published and other manuscripts are under preparation. As these is a rich repository of clinical data and biological samples, we expect many more studies will be published in the future based on this cohort

a. RM Xicola, Z Manojlovic, GJ. Augustus, SS Kupfer, R Emmadi, et al. Lack of APC somatic mutation is associated with early-onset colorectal cancer in African Americans. Carcinogenesis. 2018 Dec 13;39(11):1331-1341. PMCID: PMC6292413

b. Pibiri F, Kittles RA, Sandler RS, Keku TO, Kupfer SS, et al. Genetic variation in vitamin D-related genes and risk of colorectal cancer in African Americans. Cancer Causes Control. 2014 May;25(5):561-70. PMCID: PMC3978221.

c. Xicola RM, Gagnon M, Clark JR, Carroll T, Gao W, et al. Excess of proximal microsatellite-stable colorectal cancer in African Americans from a multiethnic study. Clin Cancer Res. 2014 Sep 15;20(18):4962-70. PMCID: PMC4167473.

d. Guindalini RS, Win AK, Gulden C, Lindor NM, Newcomb PA, et al. Mutation spectrum and risk of colorectal cancer in African American families with Lynch syndrome. Gastroenterology. 2015 Nov;149(6):1446-53. PMCID: PMC4648287.

3. Colorectal cancer is among all common malignancies one with the highest percentage of familial clustering. In fact, several hereditary colorectal cancer syndromes have already been well characterized, which has allowed the implementation of genetic screening and prophylactic and preventive measures. Nevertheless, about half of the families showing a pedigree strongly suggestive of an autosomal dominant inheritance pattern with no polyposis phenotype do not have known genetic predisposing mutations identified so far. I have carried out different studies to characterize these patients, investigating germline associations as well as distinctive carcinogenic processes in order to identify their potential biological cause. Several key features have been identified and these describe this group as a different colorectal cancer entity.

a. Llor X, Pons E, Xicola RM, Castells A, Alenda C, et al. Differential features of colorectal cancers fulfilling Amsterdam criteria without involvement of the mutator pathway. Clin Cancer Res. 2005 Oct 15;11(20):7304-10.

b. Goel A, Xicola RM, Nguyen TP, Doyle BJ, Sohn VR, et al. Aberrant DNA methylation in hereditary nonpolyposis colorectal cancer without mismatch repair deficiency. Gastroenterology. 2010 May;138(5):1854-62. PMCID: PMC2859993.

c. Rodríguez-Soler M, Pérez-Carbonell L, Guarinos C, Zapater P, Castillejo A, et al. Risk of cancer in cases of suspected lynch syndrome without germline mutation. Gastroenterology. 2013 May;144(5):926-932.e1; quiz e13-4.

b. Xicola RM, Bontu S, Doyle BJ, Rawson J, Garre P, et al. Association of a let-7 miRNA binding region of TGFBR1 with hereditary mismatch repair proficient colorectal cancer (MSS HNPCC). Carcinogenesis. 2016 Aug;37(8):751-8. PMCID: PMC4967215.

Coauthors

Research Interests

African Americans; Digestive System Neoplasms; Genetics, Medical; Genetics, Population; Colorectal Neoplasms; Lynch Syndrome II

Public Health Interests

Cancer; Nutrition; Health Equity, Disparities, Social Determinants and Justice

Selected Publications

  • Abstract 5897: Paired tumor/normal clinical sequencing enables identification of patients with pathogenic germline variantsDimopoulos C, Brierley K, Gibson J, Walther Z, Llor X. Abstract 5897: Paired tumor/normal clinical sequencing enables identification of patients with pathogenic germline variants Cancer Research 2022, 82: 5897-5897. DOI: 10.1158/1538-7445.am2022-5897.
  • Abstract 484: Molecular drivers of tumor progression in microsatellite stable APC mutation-negative colorectal cancersPadi M, Bellomo D, Grant A, Xicola R, Thorne C, Salhia B, Llor X, Ellis N. Abstract 484: Molecular drivers of tumor progression in microsatellite stable APC mutation-negative colorectal cancers Cancer Research 2022, 82: 484-484. DOI: 10.1158/1538-7445.am2022-484.
  • Tu1100: HETEROZYGOUS MUTATIONS IN DNA REPAIR GENES CONFER GENETIC SUSCEPTIILITY TO COLORECTAL CANCER AMONG LYNCH-LIKE CASESGiner-Calabuig M, De Leon S, Vidal-Pedrola G, Fehlmann T, Ukaegbu C, Gibson J, Picó M, Alenda C, Reyes J, Ortega S, LLado C, de la Torre Rubio P, Obrador-Hevia A, Castillejo A, Soto J, Castellví-Bel S, Syngal S, Stoffel E, Ellis N, Jover R, Llor X, Xicola R. Tu1100: HETEROZYGOUS MUTATIONS IN DNA REPAIR GENES CONFER GENETIC SUSCEPTIILITY TO COLORECTAL CANCER AMONG LYNCH-LIKE CASES Gastroenterology 2022, 162: s-883. DOI: 10.1016/s0016-5085(22)62088-2.
  • Simplified and more sensitive criteria for identifying individuals with pathogenic CDH1 variantsLerner BA, Xicola RM, Rodriguez NJ, Karam R, Llor X. Simplified and more sensitive criteria for identifying individuals with pathogenic CDH1 variants Journal Of Medical Genetics 2022, 60: 36-40. PMID: 35078942, PMCID: PMC9661780, DOI: 10.1136/jmedgenet-2021-108169.
  • Abstract PO-052: A multisystem approach doubles the number of patients referred for genetic testing and diagnosed with Lynch syndrome with equally success among ethnic/racial groupsSingh V, Ganzak A, Gershkovich P, Gibson J, Xicola R, Llor X. Abstract PO-052: A multisystem approach doubles the number of patients referred for genetic testing and diagnosed with Lynch syndrome with equally success among ethnic/racial groups Cancer Epidemiology Biomarkers & Prevention 2022, 31: po-052-po-052. DOI: 10.1158/1538-7755.disp21-po-052.
  • Molecular drivers of tumor progression in microsatellite stable APC mutation-negative colorectal cancersGrant A, Xicola RM, Nguyen V, Lim J, Thorne C, Salhia B, Llor X, Ellis N, Padi M. Molecular drivers of tumor progression in microsatellite stable APC mutation-negative colorectal cancers Scientific Reports 2021, 11: 23507. PMID: 34873211, PMCID: PMC8648784, DOI: 10.1038/s41598-021-02806-x.
  • COLORECTAL CANCER RISK IN LYNCH SYNDROME: OF GENES AND MOREMezzacappa C, Llor X. COLORECTAL CANCER RISK IN LYNCH SYNDROME: OF GENES AND MORE Gastroenterology 2021, 162: 1358-1360. PMID: 34863785, DOI: 10.1053/j.gastro.2021.11.032.
  • xDEEP-MSI: Explainable Bias-Rejecting Microsatellite Instability Deep Learning System in Colorectal CancerBustos A, Payá A, Torrubia A, Jover R, Llor X, Bessa X, Castells A, Carracedo Á, Alenda C. xDEEP-MSI: Explainable Bias-Rejecting Microsatellite Instability Deep Learning System in Colorectal Cancer Biomolecules 2021, 11: 1786. PMID: 34944430, PMCID: PMC8699085, DOI: 10.3390/biom11121786.
  • NCCN Guidelines® Insights: Genetic/Familial High-Risk Assessment: Colorectal, Version 1.2021.Weiss JM, Gupta S, Burke CA, Axell L, Chen LM, Chung DC, Clayback KM, Dallas S, Felder S, Gbolahan O, Giardiello FM, Grady W, Hall MJ, Hampel H, Hodan R, Idos G, Kanth P, Katona B, Lamps L, Llor X, Lynch PM, Markowitz AJ, Pirzadeh-Miller S, Samadder NJ, Shibata D, Swanson BJ, Szymaniak BM, Wiesner GL, Wolf A, Yurgelun MB, Zakhour M, Darlow SD, Dwyer MA, Campbell M. NCCN Guidelines® Insights: Genetic/Familial High-Risk Assessment: Colorectal, Version 1.2021. Journal Of The National Comprehensive Cancer Network 2021, 19: 1122-1132. PMID: 34666312, DOI: 10.1164/jnccn.2021.0048.
  • Abstract 898: Survival for patients with early-onset colorectal cancer - An overall survival analysis from the National Cancer Database, 2004-2015Cheng E, Cheng E, Blackburn H, Ng K, Ng K, Spiegelman D, Irwin M, Ma X, Gross C, Tabung F, Tabung F, Giovannucci E, Giovannucci E, Kunz P, Llor X, Billingsley K, Meyerhardt J, Meyerhardt J, Ahuja N, Fuchs C. Abstract 898: Survival for patients with early-onset colorectal cancer - An overall survival analysis from the National Cancer Database, 2004-2015 Cancer Research 2021, 81: 898-898. DOI: 10.1158/1538-7445.am2021-898.
  • Analysis of Survival Among Adults With Early-Onset Colorectal Cancer in the National Cancer DatabaseCheng E, Blackburn HN, Ng K, Spiegelman D, Irwin ML, Ma X, Gross CP, Tabung FK, Giovannucci EL, Kunz PL, Llor X, Billingsley K, Meyerhardt JA, Ahuja N, Fuchs CS. Analysis of Survival Among Adults With Early-Onset Colorectal Cancer in the National Cancer Database JAMA Network Open 2021, 4: e2112539. PMID: 34132794, PMCID: PMC8209612, DOI: 10.1001/jamanetworkopen.2021.12539.
  • Exome sequencing of early-onset patients supports genetic heterogeneity in colorectal cancerFernández-Rozadilla C, Álvarez-Barona M, Quintana I, López-Novo A, Amigo J, Cameselle-Teijeiro J, Roman E, Gonzalez D, Llor X, Bujanda L, Bessa X, Jover R, Balaguer F, Castells A, Castellví-Bel S, Capellá G, Carracedo A, Valle L, Ruiz-Ponte C. Exome sequencing of early-onset patients supports genetic heterogeneity in colorectal cancer Scientific Reports 2021, 11: 11135. PMID: 34045552, PMCID: PMC8159954, DOI: 10.1038/s41598-021-90590-z.
  • Su076 COST-EFFECTIVENESS ANALYSIS OF SCREENING STRATEGIES FOR LYNCH SYNDROME UNDER DIFFERENT SYSTEMS APPROACHESZhu J, Singh V, Gershkovich P, Ganzak A, Gibson J, Yaesoubi R, Llor X. Su076 COST-EFFECTIVENESS ANALYSIS OF SCREENING STRATEGIES FOR LYNCH SYNDROME UNDER DIFFERENT SYSTEMS APPROACHES Gastroenterology 2021, 160: s-606-s-607. DOI: 10.1016/s0016-5085(21)02152-1.
  • Dickkopf-2 regulates the stem cell marker LGR5 in colorectal cancer via HNF4α1Shin JH, Jeong J, Choi J, Lim J, Dinesh RK, Braverman J, Hong JY, Maher SE, Vesely M, Kim W, Koo JH, Tang W, Wu D, Blackburn HN, Xicola RM, Llor X, Yilmaz O, Choi JM, Bothwell ALM. Dickkopf-2 regulates the stem cell marker LGR5 in colorectal cancer via HNF4α1 IScience 2021, 24: 102411. PMID: 33997693, PMCID: PMC8099562, DOI: 10.1016/j.isci.2021.102411.
  • Phenotypic Differences in Juvenile Polyposis Syndrome With or Without a Disease-causing SMAD4/BMPR1A VariantMacFarland SP, Ebrahimzadeh JE, Zelley K, Begum L, Bass LM, Brand RE, Dudley B, Fishman DS, Ganzak A, Karloski E, Latham A, Llor X, Plon S, Riordan MK, Scollon SR, Stadler ZK, Syngal S, Ukaegbu C, Weiss JM, Yurgelun MB, Brodeur GM, Mamula P, Katona BW. Phenotypic Differences in Juvenile Polyposis Syndrome With or Without a Disease-causing SMAD4/BMPR1A Variant Cancer Prevention Research 2021, 14: 215-222. PMID: 33097490, PMCID: PMC8557953, DOI: 10.1158/1940-6207.capr-20-0348.
  • Genetic Gastric Cancer Risk SyndromesLerner BA, Llor X. Genetic Gastric Cancer Risk Syndromes Current Treatment Options In Gastroenterology 2020, 18: 604-615. PMID: 33776403, PMCID: PMC7992355, DOI: 10.1007/s11938-020-00312-z.
  • NCCN Guidelines Insights: Colorectal Cancer Screening, Version 2.2020.Provenzale D, Ness RM, Llor X, Weiss JM, Abbadessa B, Cooper G, Early DS, Friedman M, Giardiello FM, Glaser K, Gurudu S, Halverson AL, Issaka R, Jain R, Kanth P, Kidambi T, Lazenby AJ, Maguire L, Markowitz AJ, May FP, Mayer RJ, Mehta S, Patel S, Peter S, Stanich P, Terdiman J, Keller J, Dwyer MA, Ogba N. NCCN Guidelines Insights: Colorectal Cancer Screening, Version 2.2020. Journal Of The National Comprehensive Cancer Network 2020, 18: 1312-1320. PMID: 33022639, PMCID: PMC8311627, DOI: 10.6004/jnccn.2020.0048.
  • Abstract CT236: A phase 1b, multicenter, randomized, blinded, placebo-controlled study to evaluate the efficacy of guselkumab in subjects with familial adenomatous polyposisVilar-Sanchez E, Burke C, Correa M, Dekker E, Grady W, Grandval P, Katona B, Llor X, Riegert-Johnson D, Saurin J, Stanich P, Sussman D, Weinberg D, Attiyeh E, Joseph D, Raybold K, Borzillo G, Prior T, Smith M, Xie H, Bachman K, Infante J, Samadder N. Abstract CT236: A phase 1b, multicenter, randomized, blinded, placebo-controlled study to evaluate the efficacy of guselkumab in subjects with familial adenomatous polyposis Cancer Research 2020, 80: ct236-ct236. DOI: 10.1158/1538-7445.am2020-ct236.
  • AGA White Paper: Roadmap for the Future of Colorectal Cancer Screening in the United StatesMelson JE, Imperiale TF, Itzkowitz SH, Llor X, Kochman ML, Grady WM, Schoen RE, Burke CA, Shaukat A, Rabeneck L, Ladabaum U, Bresalier R, Spiegel B, Yee J, Wang T, Lieberman D, Komanduri S, Muthusamy VR, Dey N. AGA White Paper: Roadmap for the Future of Colorectal Cancer Screening in the United States Clinical Gastroenterology And Hepatology 2020, 18: 2667-2678.e2. PMID: 32634626, DOI: 10.1016/j.cgh.2020.06.053.
  • Abstract IA26: Mechanistic differences in early-onset colorectal cancerXicola R, Manojlovic Z, Augustus G, Kupfer S, Emmadi R, Alagiozian-Angelova V, Triche T, Bodour S, Carpten J, Llor X, Ellis N. Abstract IA26: Mechanistic differences in early-onset colorectal cancer Cancer Epidemiology Biomarkers & Prevention 2020, 29: ia26-ia26. DOI: 10.1158/1538-7755.disp18-ia26.
  • 1 IMPROVING LYNCH SYNDROME IDENTIFICATION THROUGH THE IMPLEMENTATION OF ENHANCED TUMOR TESTING AND A COMPREHENSIVE SYSTEMS APPROACHSingh V, Ganzak A, Gershkovich P, Gibson J, Llor X. 1 IMPROVING LYNCH SYNDROME IDENTIFICATION THROUGH THE IMPLEMENTATION OF ENHANCED TUMOR TESTING AND A COMPREHENSIVE SYSTEMS APPROACH Gastroenterology 2020, 158: s-1. DOI: 10.1016/s0016-5085(20)30682-x.
  • Tu1212 RELEVANT HETEROGENEITY IN MISMATCH REPAIR DEFICIENT TUMORSGiner-Calabuig M, Ukaegbu C, Syngal S, Stoffel E, Jover R, Llor X, Xicola R. Tu1212 RELEVANT HETEROGENEITY IN MISMATCH REPAIR DEFICIENT TUMORS Gastroenterology 2020, 158: s-1020. DOI: 10.1016/s0016-5085(20)33223-6.
  • Decreased copy‐neutral loss of heterozygosity in African American colorectal cancersAugustus GJ, Xicola RM, Llor X, Ellis NA. Decreased copy‐neutral loss of heterozygosity in African American colorectal cancers Genes Chromosomes And Cancer 2020, 59: 454-464. PMID: 32293075, PMCID: PMC8045478, DOI: 10.1002/gcc.22851.
  • "Clinical-Grade Detection of Microsatellite Instability in Colorectal Tumors by Deep LearningPractice Update
  • "Colonoscopy and Reduction of Colorectal Cancer Risk by Molecular Tumor Subtypes: A Population-Based Case-Control Study"Practice Update
  • Lynch Syndrome: Widening the NetLlor X. Lynch Syndrome: Widening the Net Gastroenterology 2019, 157: 1432-1434. PMID: 31586568, DOI: 10.1053/j.gastro.2019.09.028.
  • NCCN Guidelines Insights: Genetic/Familial High-Risk Assessment: Colorectal, Version 2.2019.Gupta S, Provenzale D, Llor X, Halverson AL, Grady W, Chung DC, Haraldsdottir S, Markowitz AJ, Slavin TP, Hampel H, Ness RM, Weiss JM, Ahnen DJ, Chen LM, Cooper G, Early DS, Giardiello FM, Hall MJ, Hamilton SR, Kanth P, Klapman JB, Lazenby AJ, Lynch PM, Mayer RJ, Mikkelson J, Peter S, Regenbogen SE, Dwyer MA, Ogba N. NCCN Guidelines Insights: Genetic/Familial High-Risk Assessment: Colorectal, Version 2.2019. Journal Of The National Comprehensive Cancer Network : JNCCN 2019, 17: 1032-1041. PMID: 31487681, DOI: 10.6004/jnccn.2019.0044.
  • Scoring colorectal cancer risk with an artificial neural network based on self-reportable personal health dataNartowt BJ, Hart GR, Roffman DA, Llor X, Ali I, Muhammad W, Liang Y, Deng J. Scoring colorectal cancer risk with an artificial neural network based on self-reportable personal health data PLOS ONE 2019, 14: e0221421. PMID: 31437221, PMCID: PMC6705772, DOI: 10.1371/journal.pone.0221421.
  • Clinical features and cancer risk in families with pathogenic CDH1 variants irrespective of clinical criteriaXicola RM, Li S, Rodriguez N, Reinecke P, Karam R, Speare V, Black MH, LaDuca H, Llor X. Clinical features and cancer risk in families with pathogenic CDH1 variants irrespective of clinical criteria Journal Of Medical Genetics 2019, 56: 838. PMID: 31296550, DOI: 10.1136/jmedgenet-2019-105991.
  • Implication of DNA repair genes in Lynch-like syndromeXicola RM, Clark JR, Carroll T, Alvikas J, Marwaha P, Regan MR, Lopez-Giraldez F, Choi J, Emmadi R, Alagiozian-Angelova V, Kupfer SS, Ellis NA, Llor X. Implication of DNA repair genes in Lynch-like syndrome Familial Cancer 2019, 18: 331-342. PMID: 30989425, PMCID: PMC6561810, DOI: 10.1007/s10689-019-00128-6.
  • "Oral Antibiotic Use and Risk of Colorectal Cancer in the United Kingdom"Practice Update
  • Lack of APC somatic mutation is associated with early-onset colorectal cancer in African Americans.Xicola RM, Manojlovic Z, Augustus GJ, Kupfer SS, Emmadi R, Alagiozian-Angelova V, Triche T, Salhia B, Carpten J, Llor X, Ellis NA. Lack of APC somatic mutation is associated with early-onset colorectal cancer in African Americans. Carcinogenesis 2018, 39: 1331-1341. PMID: 30239619, PMCID: PMC6292413, DOI: 10.1093/carcin/bgy122.
  • Colorectal cancer molecular classification using BRAF, KRAS, microsatellite instability and CIMP status: Prognostic implications and response to chemotherapyMurcia O, Juárez M, Rodríguez-Soler M, Hernández-Illán E, Giner-Calabuig M, Alustiza M, Egoavil C, Castillejo A, Alenda C, Barberá V, Mangas-Sanjuan C, Yuste A, Bujanda L, Clofent J, Andreu M, Castells A, Llor X, Zapater P, Jover R. Colorectal cancer molecular classification using BRAF, KRAS, microsatellite instability and CIMP status: Prognostic implications and response to chemotherapy PLOS ONE 2018, 13: e0203051. PMID: 30188916, PMCID: PMC6126803, DOI: 10.1371/journal.pone.0203051.
  • NCCN Guidelines Insights: Colorectal Cancer Screening, Version 1.2018.Provenzale D, Gupta S, Ahnen DJ, Markowitz AJ, Chung DC, Mayer RJ, Regenbogen SE, Blanco AM, Bray T, Cooper G, Early DS, Ford JM, Giardiello FM, Grady W, Hall MJ, Halverson AL, Hamilton SR, Hampel H, Klapman JB, Larson DW, Lazenby AJ, Llor X, Lynch PM, Mikkelson J, Ness RM, Slavin TP, Sugandha S, Weiss JM, Dwyer MA, Ogba N. NCCN Guidelines Insights: Colorectal Cancer Screening, Version 1.2018. Journal Of The National Comprehensive Cancer Network : JNCCN 2018, 16: 939-949. PMID: 30099370, DOI: 10.6004/jnccn.2018.0067.
  • TFAP2E Methylation and Expression Status Does Not Predict Response to 5-FU-based Chemotherapy in Colorectal CancerMurcia O, Jover R, Egoavil C, Perez-Carbonell L, Juárez M, Hernández-Illán E, Rojas E, Alenda C, Balaguer F, Andreu M, Llor X, Castells A, Boland CR, Goel A. TFAP2E Methylation and Expression Status Does Not Predict Response to 5-FU-based Chemotherapy in Colorectal Cancer Clinical Cancer Research 2018, 24: 2820-2827. PMID: 29535127, PMCID: PMC7396148, DOI: 10.1158/1078-0432.ccr-17-2940.
  • 1066 - Phenotypic Expression of Cdh1 Germline Mutations Unselected for Hereditary Diffuse Gastric CancerRodriguez N, Reineke P, LaDuca H, Xicola R, Llor X. 1066 - Phenotypic Expression of Cdh1 Germline Mutations Unselected for Hereditary Diffuse Gastric Cancer Gastroenterology 2018, 154: s-204. DOI: 10.1016/s0016-5085(18)31081-3.
  • Genetic testing for hereditary prostate cancer: Current status and limitationsZhen JT, Syed J, Nguyen KA, Leapman MS, Agarwal N, Brierley K, Llor X, Hofstatter E, Shuch B. Genetic testing for hereditary prostate cancer: Current status and limitations Cancer 2018, 124: 3105-3117. PMID: 29669169, DOI: 10.1002/cncr.31316.
  • Colorectal cancer molecular classification using BRAF, KRAS, microsatellite instability, and CIMP status: Prognostic implications and response to chemotherapy.Murcia O, Juárez M, Hernández-Illán E, Rodriguez-Soler M, Giner-Calabuig M, Alustiza M, Egoavil C, Castillejo A, Alenda C, Mangas C, Barberá V, Yuste A, Bujanda L, Clofent J, Andreu M, Castells A, Llor X, Zapater P, Jover R. Colorectal cancer molecular classification using BRAF, KRAS, microsatellite instability, and CIMP status: Prognostic implications and response to chemotherapy. Journal Of Clinical Oncology 2018, 36: 668-668. DOI: 10.1200/jco.2018.36.4_suppl.668.
  • "Lynch Syndrome Cancer Risk and Survival by Genotype"Practice Update
  • "Germline Mutations in BRF1 Increase Risk of Hereditary Colorectal Cancer"Practice Update
  • "Genetic Risk Score is Associated With Prevalence of Advance Neoplasms in a CRC Screening Population"Practice Update
  • "Prevalence of and Risk Factors for Colorectal Neoplasia in Asymptomatic Young AdultsPractice Update
  • NCCN Guidelines Insights: Genetic/Familial High-Risk Assessment: Colorectal, Version 3.2017.Gupta S, Provenzale D, Regenbogen SE, Hampel H, Slavin TP, Hall MJ, Llor X, Chung DC, Ahnen DJ, Bray T, Cooper G, Early DS, Ford JM, Giardiello FM, Grady W, Halverson AL, Hamilton SR, Klapman JB, Larson DW, Lazenby AJ, Lynch PM, Markowitz AJ, Mayer RJ, Ness RM, Samadder NJ, Shike M, Sugandha S, Weiss JM, Dwyer MA, Ogba N. NCCN Guidelines Insights: Genetic/Familial High-Risk Assessment: Colorectal, Version 3.2017. Journal Of The National Comprehensive Cancer Network : JNCCN 2017, 15: 1465-1475. PMID: 29223984, DOI: 10.6004/jnccn.2017.0176.
  • Abdominal Pain With Boring-Like Character: The Revolution Is Yet to Come.Llor X. Abdominal Pain With Boring-Like Character: The Revolution Is Yet to Come. Journal Of The National Comprehensive Cancer Network : JNCCN 2017, 15: 969-970. PMID: 28687583, DOI: 10.6004/jnccn.2017.0128.
  • Abstract 1759: Description of molecular marker disparities and KRAS mutational spectrum of colorectal tumors from Puerto Rican HispanicsPerez-Mayoral J, Rivera-Lynch C, Soto-Salgado M, Llor X, Tous-Lopez L, Torres-Torres M, Reyes J, Torres C, Goel A, Rodriguez-Quillichini S, Cruz-Correa M. Abstract 1759: Description of molecular marker disparities and KRAS mutational spectrum of colorectal tumors from Puerto Rican Hispanics Cancer Research 2017, 77: 1759-1759. DOI: 10.1158/1538-7445.am2017-1759.
  • Methylation of WNT target genes AXIN2 and DKK1 as robust biomarkers for recurrence prediction in stage II colon cancerKandimalla R, Linnekamp JF, van Hooff S, Castells A, Llor X, Andreu M, Jover R, Goel A, Medema JP. Methylation of WNT target genes AXIN2 and DKK1 as robust biomarkers for recurrence prediction in stage II colon cancer Oncogenesis 2017, 6: e308-e308. PMID: 28368388, PMCID: PMC5520503, DOI: 10.1038/oncsis.2017.9.
  • 235 Mutational and Epigenetic Spectrum of Colorectal Cancers in African AmericansXicola R, Manojlovic Z, Augustus G, Kupfer S, Carpten J, Ellis N, Llor X. 235 Mutational and Epigenetic Spectrum of Colorectal Cancers in African Americans Gastroenterology 2017, 152: s60. DOI: 10.1016/s0016-5085(17)30558-9.
  • 86 Outcomes and Cost Analysis of a Colonoscopy-Based Colorectal Cancer Screening Program in a Lower Income us Hispanic CohortAlvarenga J, Kwak Y, Vazquez-Gillamet L, Vargas-Torres M, Vega M, Lagarde S, McCloskey B, Xicola R, Llor X. 86 Outcomes and Cost Analysis of a Colonoscopy-Based Colorectal Cancer Screening Program in a Lower Income us Hispanic Cohort Gastroenterology 2017, 152: s23. DOI: 10.1016/s0016-5085(17)30447-x.
  • Su1014 Resource Utilization and Colorectal Cancer Screening Compliance with Patient Navigation in Under-Screened PopulationsKwak Y, Alvarenga J, Vazquez-Gillamet L, Vega M, Vargas-Torres M, Lagarde S, McCloskey B, Xicola R, Llor X. Su1014 Resource Utilization and Colorectal Cancer Screening Compliance with Patient Navigation in Under-Screened Populations Gastroenterology 2017, 152: s443. DOI: 10.1016/s0016-5085(17)31692-x.
  • Tu1974 Molecular Disparities and Kras Mutational Spectrum of Colorectal Tumors from Puerto Rican Hispanic SubjectsMarquez J, Pérez-Mayoral J, Gonzalez-Pons M, Rodriguez-Mañon N, Rivera-Lynch C, Soto M, Llor X, Xicola R, Lopez L, Torres-Torres M, Reyes J, Goel A, Torres-Cintrón C, Rodriguez-Quilichini S, Cruz-Correa M. Tu1974 Molecular Disparities and Kras Mutational Spectrum of Colorectal Tumors from Puerto Rican Hispanic Subjects Gastroenterology 2017, 152: s1022. DOI: 10.1016/s0016-5085(17)33461-3.
  • Race-dependent association of sulfidogenic bacteria with colorectal cancerYazici C, Wolf PG, Kim H, Cross TL, Vermillion K, Carroll T, Augustus GJ, Mutlu E, Tussing-Humphreys L, Braunschweig C, Xicola RM, Jung B, Llor X, Ellis NA, Gaskins HR. Race-dependent association of sulfidogenic bacteria with colorectal cancer Gut 2017, 66: 1983. PMID: 28153960, PMCID: PMC5575988, DOI: 10.1136/gutjnl-2016-313321.
  • Abstract B31: Sulfidogenic bacteria are an important diet-driven exposure promoting colorectal cancer in African AmericansYazici C, Wolf P, Liu T, Vermillion K, Carroll T, Mutlu E, Tussing-Humphreys L, Braunschweig C, Xicola R, Jung B, Llor X, Ellis N, Gaskins H. Abstract B31: Sulfidogenic bacteria are an important diet-driven exposure promoting colorectal cancer in African Americans Cancer Epidemiology Biomarkers & Prevention 2017, 26: b31-b31. DOI: 10.1158/1538-7755.disp16-b31.
  • "Dietary Patterns and Risk of Colorectal Cancer: Analysis by Tumor Location and Molecular Subtypes"Practice Update
  • "Interval Colorectal Cancer Incidence Among Subjects Undergoing Multiple Rounds of Fecal Immunochemical Testing"Practice Update
  • Candidate predisposing germline copy number variants in early onset colorectal cancer patientsBrea-Fernandez AJ, Fernandez-Rozadilla C, Alvarez-Barona M, Azuara D, Ginesta MM, Clofent J, de Castro L, Gonzalez D, Andreu M, Bessa X, Llor X, Xicola R, Jover R, Castells A, Castellvi-Bel S, Capella G, Carracedo A, Ruiz-Ponte C. Candidate predisposing germline copy number variants in early onset colorectal cancer patients Clinical And Translational Oncology 2016, 19: 625-632. PMID: 27888432, DOI: 10.1007/s12094-016-1576-z.
  • Building a Cancer Genetics and Prevention ProgramLlor X. Building a Cancer Genetics and Prevention Program Clinical Gastroenterology And Hepatology 2016, 14: 1516-1520. PMID: 27531499, DOI: 10.1016/j.cgh.2016.06.012.
  • Abstract 5013: A meta-analysis of MSI frequency and race in colorectal cancerAshktorab H, Ahuja S, Kannan L, Llor X, Ellis N, Xicola R, Laiyemo A, Carethers J, Brim H, Nouraie M. Abstract 5013: A meta-analysis of MSI frequency and race in colorectal cancer Cancer Research 2016, 76: 5013-5013. DOI: 10.1158/1538-7445.am2016-5013.
  • Kinase-Dependent and -Independent Roles for PTK6 in Colon CancerMathur PS, Gierut JJ, Guzman G, Xie H, Xicola RM, Llor X, Chastkofsky MI, Perekatt AO, Tyner AL. Kinase-Dependent and -Independent Roles for PTK6 in Colon Cancer Molecular Cancer Research 2016, 14: 563-573. PMID: 26983689, PMCID: PMC4912439, DOI: 10.1158/1541-7786.mcr-15-0450.
  • Association of a let-7 miRNA binding region of TGFBR1 with hereditary mismatch repair proficient colorectal cancer (MSS HNPCC).Xicola RM, Bontu S, Doyle BJ, Rawson J, Garre P, Lee E, de la Hoya M, Bessa X, Clofent J, Bujanda L, Balaguer F, Castellví-Bel S, Alenda C, Jover R, Ruiz-Ponte C, Syngal S, Andreu M, Carracedo A, Castells A, Newcomb PA, Lindor N, Potter JD, Baron JA, Ellis NA, Caldes T, LLor X. Association of a let-7 miRNA binding region of TGFBR1 with hereditary mismatch repair proficient colorectal cancer (MSS HNPCC). Carcinogenesis 2016, 37: 751-8. PMID: 27234654, PMCID: PMC4967215, DOI: 10.1093/carcin/bgw064.
  • A meta-analysis of MSI frequency and race in colorectal cancerAshktorab H, Ahuja S, Kannan L, Llor X, Ellis NA, Xicola RM, Laiyemo AO, Carethers JM, Brim H, Nouraie M. A meta-analysis of MSI frequency and race in colorectal cancer Oncotarget 2016, 7: 34546-34557. PMID: 27120810, PMCID: PMC5085175, DOI: 10.18632/oncotarget.8945.
  • 775 Unveiling New Colorectal Cancer Phenotypes With Mismatch Repair DeficiencyXicola R, Clark J, Carroll T, Alvikas J, Marwaha P, Regan M, Emmadi R, Alagiozian-Angelova V, Kupfer S, Ellis N, Llor X. 775 Unveiling New Colorectal Cancer Phenotypes With Mismatch Repair Deficiency Gastroenterology 2016, 150: s160. DOI: 10.1016/s0016-5085(16)30630-8.
  • Abstract B35: Molecular characterization of colorectal tumors from Puerto Rican Hispanic patientsDíaz-Algorri Y, Pérez-Mayoral J, González-Pons M, Rodríguez N, Suárez B, Colón G, Sevilla J, Jorge D, Llor X, Xicola R, Tous L, Reyes J, Torres M, Goel A, Rodriguez S, Cruz-Correa M. Abstract B35: Molecular characterization of colorectal tumors from Puerto Rican Hispanic patients Cancer Epidemiology Biomarkers & Prevention 2016, 25: b35-b35. DOI: 10.1158/1538-7755.disp15-b35.
  • Abstract PR02: Homologous recombination drives African American colorectal carcinogenesisAugustus G, Xicola R, Brothman A, Llor X, Ellis N. Abstract PR02: Homologous recombination drives African American colorectal carcinogenesis Cancer Epidemiology Biomarkers & Prevention 2016, 25: pr02-pr02. DOI: 10.1158/1538-7755.disp15-pr02.
  • "Risk of Colorectal Neoplasia in Individuals with Self-Reported Family History"Practice Update
  • "Increased Uptake and Improved Outcomes of Bowel Cancer Screening with a Fecal Immunochemical Test"Practice Update
  • Abstract A75: Excess of proximal microsatellite-stable colorectal cancer in African Americans from a multiethnic studyXicola R, Kupfer S, Braunschweig C, Ellis N, Llor X. Abstract A75: Excess of proximal microsatellite-stable colorectal cancer in African Americans from a multiethnic study Cancer Epidemiology Biomarkers & Prevention 2015, 24: a75-a75. DOI: 10.1158/1538-7755.disp14-a75.
  • Mutation Spectrum and Risk of Colorectal Cancer in African American Families with Lynch SyndromeSanta Cruz Guindalini R, Win AK, Gulden C, Lindor NM, Newcomb PA, Haile RW, Raymond V, Stoffel E, Hall M, Llor X, Ukaegbu CI, Solomon I, Weitzel J, Kalady M, Blanco A, Terdiman J, Shuttlesworth GA, Lynch PM, Hampel H, Lynch HT, Jenkins MA, Olopade OI, Kupfer SS. Mutation Spectrum and Risk of Colorectal Cancer in African American Families with Lynch Syndrome Gastroenterology 2015, 149: 1446-1453. PMID: 26248088, PMCID: PMC4648287, DOI: 10.1053/j.gastro.2015.07.052.
  • Abstract 4582: Enrichment of colorectal cancer and inflammatory bowel disease risk variants in colon expression quantitative trait loci in African AmericansKupfer S, Hulur I, Gamazon E, Skol A, Llor X, Onel K, Ellis N. Abstract 4582: Enrichment of colorectal cancer and inflammatory bowel disease risk variants in colon expression quantitative trait loci in African Americans 2015, 4582-4582. DOI: 10.1158/1538-7445.am2015-4582.
  • Abstract LB-059: Opposing roles for protein tyrosine kinase 6 (PTK6) in colon cancerMathur P, Gierut J, Xicola R, Llor X, Tyner A. Abstract LB-059: Opposing roles for protein tyrosine kinase 6 (PTK6) in colon cancer 2015, lb-059-lb-059. DOI: 10.1158/1538-7445.am2015-lb-059.
  • Efficacy of Adjuvant 5-Fluorouracil Therapy for Patients with EMAST-Positive Stage II/III Colorectal CancerHamaya Y, Guarinos C, Tseng-Rogenski SS, Iwaizumi M, Das R, Jover R, Castells A, Llor X, Andreu M, Carethers JM. Efficacy of Adjuvant 5-Fluorouracil Therapy for Patients with EMAST-Positive Stage II/III Colorectal Cancer PLOS ONE 2015, 10: e0127591. PMID: 25996601, PMCID: PMC4440728, DOI: 10.1371/journal.pone.0127591.
  • Prevalence of MLH1 constitutional epimutations as a cause of Lynch syndrome in unselected versus selected consecutive series of patients with colorectal cancerCastillejo A, Hernández-Illán E, Rodriguez-Soler M, Pérez-Carbonell L, Egoavil C, Barberá VM, Castillejo MI, Guarinos C, Martínez-de-Dueñas E, Juan MJ, Sánchez-Heras AB, García-Casado Z, Ruiz-Ponte C, Brea-Fernández A, Juárez M, Bujanda L, Clofent J, Llor X, Andreu M, Castells A, Carracedo A, Alenda C, Payá A, Jover R, Soto JL. Prevalence of MLH1 constitutional epimutations as a cause of Lynch syndrome in unselected versus selected consecutive series of patients with colorectal cancer Journal Of Medical Genetics 2015, 52: 498. PMID: 25908759, DOI: 10.1136/jmedgenet-2015-103076.
  • Su1993 Somatic Mutations in the Mismatch Repair System Are Responsible for a Majority of Unexplained Lynch Syndrome Cases: Time to Revise Lynch Syndrome Screening?Xicola R, Carroll T, Emmadi R, Alagiozian-Angelova V, Alvikas J, Marwaha P, Regan M, Gibson J, Mitchell K, Kupfer S, Ellis N, Llor X. Su1993 Somatic Mutations in the Mismatch Repair System Are Responsible for a Majority of Unexplained Lynch Syndrome Cases: Time to Revise Lynch Syndrome Screening? Gastroenterology 2015, 148: s-570. DOI: 10.1016/s0016-5085(15)31922-3.
  • Su1997 Colorectal Cancer With Methylator Phenotype. Clinical Characterisitics, Prognosis and Response to Adjuvant ChemotherapyMurcia O, Rodriguez-Soler M, Juarez-Quesada M, Guarinos C, Hernandez-Illan E, Andreu M, Castells A, Llor X, Carracedo A, Jover R. Su1997 Colorectal Cancer With Methylator Phenotype. Clinical Characterisitics, Prognosis and Response to Adjuvant Chemotherapy Gastroenterology 2015, 148: s-570-s-571. DOI: 10.1016/s0016-5085(15)31926-0.
  • 511 Bilophila wadsworthia Is More Abundant in the Colonic Microbiome of Colorectal Cancer Cases Compared to Healthy ControlsYazici C, Wolf P, Carroll T, Mutlu E, Xicola R, Llor X, Jung B, Ellis N, Gaskins H. 511 Bilophila wadsworthia Is More Abundant in the Colonic Microbiome of Colorectal Cancer Cases Compared to Healthy Controls Gastroenterology 2015, 148: s-100. DOI: 10.1016/s0016-5085(15)30343-7.
  • Enrichment of inflammatory bowel disease and colorectal cancer risk variants in colon expression quantitative trait lociHulur I, Gamazon ER, Skol AD, Xicola RM, Llor X, Onel K, Ellis NA, Kupfer SS. Enrichment of inflammatory bowel disease and colorectal cancer risk variants in colon expression quantitative trait loci BMC Genomics 2015, 16: 138. PMID: 25766683, PMCID: PMC4351699, DOI: 10.1186/s12864-015-1292-z.
  • "Improving Referral of Patients with a Familial Risk for Colorectal Cancer"Commentary
  • "Adenoma Burden in Lynch Syndrome"Commentary
  • "Stool Testing for Colorectal Cancer"Commentary
  • "Increased CRC Risk Among Family Members of All Ages"Commentary
  • "Fecal Hemoglobin Concentration Predicts Risk of Interval CancersPractice Update
  • Prevalence of somatic mutl homolog 1 promoter hypermethylation in Lynch syndrome colorectal cancerMoreira L, Muñoz J, Cuatrecasas M, Quintanilla I, Leoz ML, Carballal S, Ocaña T, López‐Cerón M, Pellise M, Castellví‐Bel S, Jover R, Andreu M, Carracedo A, Xicola RM, Llor X, Boland CR, Goel A, Castells A, Balaguer F. Prevalence of somatic mutl homolog 1 promoter hypermethylation in Lynch syndrome colorectal cancer Cancer 2014, 121: 1395-1404. PMID: 25557234, DOI: 10.1002/cncr.29190.
  • Abstract 1279: Association between vitamin D levels and colorectal cancer in African AmericansSiddiqi S, Pibiri F, Xicola R, Kittles R, Llor X, Kupfer S, Ellis N. Abstract 1279: Association between vitamin D levels and colorectal cancer in African Americans 2014, 1279-1279. DOI: 10.1158/1538-7445.am2014-1279.
  • Abstract 2191: Identification of functional risk alleles in colorectal cancer-associated regions in African AmericansPibiri F, Rechenmacher R, Xicola R, Kittles R, Sandler R, Keku T, Llor X, Carpten J, Kupfer S, Ellis N. Abstract 2191: Identification of functional risk alleles in colorectal cancer-associated regions in African Americans 2014, 2191-2191. DOI: 10.1158/1538-7445.am2014-2191.
  • Excess of Proximal Microsatellite-Stable Colorectal Cancer in African Americans from a Multiethnic StudyXicola RM, Gagnon M, Clark JR, Carroll T, Gao W, Fernandez C, Mijic D, Rawson JB, Janoski A, Pusatcioglu CK, Rajaram P, Gluskin AB, Regan M, Chaudhry V, Abcarian H, Blumetti J, Cintron J, Melson J, Xie H, Guzman G, Emmadi R, Alagiozian-Angelova V, Kupfer SS, Braunschweig C, Ellis NA, Llor X. Excess of Proximal Microsatellite-Stable Colorectal Cancer in African Americans from a Multiethnic Study Clinical Cancer Research 2014, 20: 4962-4970. PMID: 25013126, PMCID: PMC4167473, DOI: 10.1158/1078-0432.ccr-14-0353.
  • IGFBP3 Methylation Is a Novel Diagnostic and Predictive Biomarker in Colorectal CancerPerez-Carbonell L, Balaguer F, Toiyama Y, Egoavil C, Rojas E, Guarinos C, Andreu M, Llor X, Castells A, Jover R, Boland CR, Goel A. IGFBP3 Methylation Is a Novel Diagnostic and Predictive Biomarker in Colorectal Cancer PLOS ONE 2014, 9: e104285. PMID: 25127039, PMCID: PMC4134211, DOI: 10.1371/journal.pone.0104285.
  • Systemic and tumor level iron regulation in men with colorectal cancer: a case control studyPusatcioglu CK, Nemeth E, Fantuzzi G, Llor X, Freels S, Tussing-Humphreys L, Cabay RJ, Linzmeier R, Ng D, Clark J, Braunschweig C. Systemic and tumor level iron regulation in men with colorectal cancer: a case control study Nutrition & Metabolism 2014, 11: 21. PMID: 24872837, PMCID: PMC4037273, DOI: 10.1186/1743-7075-11-21.
  • Mo1153 Association of a Variant in FADS2 the Gene Encoding the Polyunsaturated Fatty Acid Metabolizing Enzyme FADS2 With Colorectal Cancer in African AmericansRavella S, Xicola R, Pibiri F, Carroll T, Sandler R, Kupfer S, Ellis N, Llor X. Mo1153 Association of a Variant in FADS2 the Gene Encoding the Polyunsaturated Fatty Acid Metabolizing Enzyme FADS2 With Colorectal Cancer in African Americans Gastroenterology 2014, 146: s-571. DOI: 10.1016/s0016-5085(14)62069-2.
  • 50 PTK6 Antagonizes the EMT in Colon Cancer Cell LinesMathur P, Xicola R, Llor X, Tyner A. 50 PTK6 Antagonizes the EMT in Colon Cancer Cell Lines Gastroenterology 2014, 146: s-14. DOI: 10.1016/s0016-5085(14)60050-0.
  • Sa1897 Novel Evidence for Interleukin-8 (IL-8) As a Predictive Biomarker of Response to 5fluorouracil Based Chemotherapy in Colorectal CancerPérez-Carbonell L, Egoavil C, Rojas E, Alenda C, Rodriguez-Soler M, Guarinos C, Juarez-Quesada M, Andreu M, Llor X, Castells A, Jover R, Boland C, Goel A. Sa1897 Novel Evidence for Interleukin-8 (IL-8) As a Predictive Biomarker of Response to 5fluorouracil Based Chemotherapy in Colorectal Cancer Gastroenterology 2014, 146: s-323. DOI: 10.1016/s0016-5085(14)61166-5.
  • 675 Unveiling of DNA Repair Gene Alterations in Non-Lynch Hereditary Colorectal Cancer Through Exome SequencingMarwaha P, Xicola R, Kim Y, Snyder C, Carroll T, Syngal S, Buxbaum S, Zhang M, Want S, Lynch H, Bessa X, Andreu M, Jover R, Carracedo A, Castells A, Caldes T, Ellis N, Llor X. 675 Unveiling of DNA Repair Gene Alterations in Non-Lynch Hereditary Colorectal Cancer Through Exome Sequencing Gastroenterology 2014, 146: s-119. DOI: 10.1016/s0016-5085(14)60429-7.
  • 719 Expression Quantitative Trait Loci Mapping in the Human ColonHulur I, Skol A, Llor X, Onel K, Ellis N, Kupfer S. 719 Expression Quantitative Trait Loci Mapping in the Human Colon Gastroenterology 2014, 146: s-125-s-126. DOI: 10.1016/s0016-5085(14)60451-0.
  • The MLH1 c.1852_1853delinsGC (p.K618A) Variant in Colorectal Cancer: Genetic Association Study in 18,723 IndividualsAbulí A, Bujanda L, Muñoz J, Buch S, Schafmayer C, Valeria Maiorana M, Veneroni S, van Wezel T, Liu T, Westers H, Esteban-Jurado C, Ocaña T, Piqué JM, Andreu M, Jover R, Carracedo A, Xicola RM, Llor X, Castells A, , Dunlop M, Hofstra R, Lindblom A, Wijnen J, Peterlongo P, Hampe J, Ruiz-Ponte C, Castellví-Bel S. The MLH1 c.1852_1853delinsGC (p.K618A) Variant in Colorectal Cancer: Genetic Association Study in 18,723 Individuals PLOS ONE 2014, 9: e95022. PMID: 24743384, PMCID: PMC3990597, DOI: 10.1371/journal.pone.0095022.
  • Cáncer colorrectal: del laboratorio al paciente, un paso ya imprescindibleLlor X. Cáncer colorrectal: del laboratorio al paciente, un paso ya imprescindible Revista De Gastroenterología De México 2014, 79: 71-72. PMID: 24934514, DOI: 10.1016/j.rgmx.2014.05.005.
  • Colorectal cancer: From the laboratory to the patient, a now indispensable stepLlor X. Colorectal cancer: From the laboratory to the patient, a now indispensable step Revista De Gastroenterología De México (English Edition) 2014, 79: 71-72. DOI: 10.1016/j.rgmxen.2014.05.012.
  • Multiple Sporadic Colorectal Cancers Display a Unique Methylation PhenotypeGonzalo V, Lozano JJ, Alonso-Espinaco V, Moreira L, Muñoz J, Pellisé M, Castellví-Bel S, Bessa X, Andreu M, Xicola RM, Llor X, Ruiz-Ponte C, Carracedo A, Jover R, Castells A, Balaguer F, . Multiple Sporadic Colorectal Cancers Display a Unique Methylation Phenotype PLOS ONE 2014, 9: e91033. PMID: 24643221, PMCID: PMC3958343, DOI: 10.1371/journal.pone.0091033.
  • Genetic variation in vitamin D-related genes and risk of colorectal cancer in African AmericansPibiri F, Kittles RA, Sandler RS, Keku TO, Kupfer SS, Xicola RM, Llor X, Ellis NA. Genetic variation in vitamin D-related genes and risk of colorectal cancer in African Americans Cancer Causes & Control 2014, 25: 561-570. PMID: 24562971, PMCID: PMC3978221, DOI: 10.1007/s10552-014-0361-y.
  • "Video Capsule Endoscopy Detection of Small Bowel Neoplasia in Lynch Syndrome"Commentary
  • "Fecal Immunochemical Tests and Colonoscopy in Colorectal Cancer Screening"Commentary
  • A genome-wide association study on copy-number variation identifies a 11q11 loss as a candidate susceptibility variant for colorectal cancerFernandez-Rozadilla C, Cazier JB, Tomlinson I, Brea-Fernández A, Lamas MJ, Baiget M, López-Fernández LA, Clofent J, Bujanda L, Gonzalez D, de Castro L, The EPICOLON Consortium, Hemminki K, Bessa X, Andreu M, Jover R, Xicola R, Llor X, Moreno V, Castells A, Castellví-Bel S, Carracedo A, Ruiz-Ponte C. A genome-wide association study on copy-number variation identifies a 11q11 loss as a candidate susceptibility variant for colorectal cancer Human Genetics 2013, 133: 525-534. PMID: 24218287, DOI: 10.1007/s00439-013-1390-4.
  • Identification of Novel Predictor Classifiers for Inflammatory Bowel Disease by Gene Expression ProfilingMontero-Meléndez T, Llor X, García-Planella E, Perretti M, Suárez A. Identification of Novel Predictor Classifiers for Inflammatory Bowel Disease by Gene Expression Profiling PLOS ONE 2013, 8: e76235. PMID: 24155895, PMCID: PMC3796518, DOI: 10.1371/journal.pone.0076235.
  • Racial Differences in Colorectal Cancer: A Large Single Institution ExperienceParepally M, Rajaram P, Xicola R, Ellis N, Llor X, Venepalli N. Racial Differences in Colorectal Cancer: A Large Single Institution Experience The American Journal Of Gastroenterology 2013, 108: s180. DOI: 10.14309/00000434-201310001-00613.
  • Genetic susceptibility variants associated with colorectal cancer prognosisAbulí A, Lozano JJ, Rodríguez-Soler M, Jover R, Bessa X, Muñoz J, Esteban-Jurado C, Fernández-Rozadilla C, Carracedo A, Ruiz-Ponte C, Cubiella J, Balaguer F, Bujanda L, Reñé JM, Clofent J, Morillas JD, Nicolás-Pérez D, Xicola RM, Llor X, Piqué JM, Andreu M, Castells A, Castellví-Bel S. Genetic susceptibility variants associated with colorectal cancer prognosis Carcinogenesis 2013, 34: 2286-2291. PMID: 23712746, DOI: 10.1093/carcin/bgt179.
  • Sa2002 IGFBP3 Methylation As a Novel Diagnostic and Prognostic Marker in Colorectal CancerPérez-Carbonell L, Toiyama Y, Balaguer F, Guarinos C, Hur K, Andreu M, Llor X, Castells A, Jover R, Boland C, Goel A. Sa2002 IGFBP3 Methylation As a Novel Diagnostic and Prognostic Marker in Colorectal Cancer Gastroenterology 2013, 144: s-356. DOI: 10.1016/s0016-5085(13)61311-6.
  • 470 TFAP2E Methylation and Expression Status Do Not Serve As Predictors of Response to 5-FU Based Chemotherapy in Colorectal CancerPérez-Carbonell L, Egoavil C, Toiyama Y, Guarinos C, Rojas E, Alenda C, Balaguer F, Hur K, Andreu M, Llor X, Castells A, Jover R, Boland C, Goel A. 470 TFAP2E Methylation and Expression Status Do Not Serve As Predictors of Response to 5-FU Based Chemotherapy in Colorectal Cancer Gastroenterology 2013, 144: s-84-s-85. DOI: 10.1016/s0016-5085(13)60314-5.
  • 106 Implication of the 3′Utr Region of TGFβR1 With MSS HNPCC and Sporadic Colorectal CancerXicola R, Doyle B, Rawson J, Garre P, Abulí A, Murugappan S, Lee J, Bessa X, Clofent J, Bujanda L, Balaguer F, Castellvi-Bel S, Alenda C, Jover R, Ruiz-Ponte C, Syngal S, Andreu M, Carracedo A, Castells A, Ellis N, Caldes T, Llor X. 106 Implication of the 3′Utr Region of TGFβR1 With MSS HNPCC and Sporadic Colorectal Cancer Gastroenterology 2013, 144: s-25. DOI: 10.1016/s0016-5085(13)60086-4.
  • Su1087 Clinicopathological Characterization and Nutritional Assessment of Hispanics With Sporadic Microsatellite Unstable Colorectal CancersDiaz-Algorri Y, Xicola R, Llor X, Tucker K, Cruz-Correa M. Su1087 Clinicopathological Characterization and Nutritional Assessment of Hispanics With Sporadic Microsatellite Unstable Colorectal Cancers Gastroenterology 2013, 144: s-395. DOI: 10.1016/s0016-5085(13)61454-7.
  • 107 Somatic MLH1 Promoter Hypermethylation Is a Frequent Event in Lynch Syndrome Colorectal CancersMoreira L, Munoz J, Cuatrecasas M, Quintanilla I, Leoz M, Carballal S, Ocana T, Fernandez P, Arnold M, Pellise M, Jover R, Andreu M, Carracedo A, Llor X, Boland C, Goel A, Castells A, Balaguer F. 107 Somatic MLH1 Promoter Hypermethylation Is a Frequent Event in Lynch Syndrome Colorectal Cancers Gastroenterology 2013, 144: s-25. DOI: 10.1016/s0016-5085(13)60087-6.
  • Abstract 1330: Genetic variation in the vitamin D pathway and risk for colorectal cancer in African Americans.Pibiri F, Ellis N, Kittles R, LLor X, Xicola R, Kupfer S, Sandler R, Keku T. Abstract 1330: Genetic variation in the vitamin D pathway and risk for colorectal cancer in African Americans. Cancer Research 2013, 73: 1330-1330. DOI: 10.1158/1538-7445.am2013-1330.
  • Abstract 1334: Implication of the 3′UTR region of TGFβR1 with MSS HNPCC and sporadic colorectal cancer.Munoz Xicola R, Doyle B, Rawson J, Garre P, Abuli A, Lee E, Murugappan S, Bessa X, Bujanda L, Balaguer F, Castellvi-Bel S, Clofent J, Alenda C, Jover R, Ruiz-Ponte C, Singal S, Andreu M, Carracedo A, Castells A, Ellis N, Caldes T, LLor X. Abstract 1334: Implication of the 3′UTR region of TGFβR1 with MSS HNPCC and sporadic colorectal cancer. Cancer Research 2013, 73: 1334-1334. DOI: 10.1158/1538-7445.am2013-1334.
  • A colorectal cancer genome-wide association study in a Spanish cohort identifies two variants associated with colorectal cancer risk at 1p33 and 8p12Fernandez-Rozadilla C, Cazier JB, Tomlinson IP, Carvajal-Carmona LG, Palles C, Lamas MJ, Baiget M, López-Fernández LA, Brea-Fernández A, Abulí A, Bujanda L, Clofent J, Gonzalez D, Xicola R, Andreu M, Bessa X, Jover R, Llor X, The EPICOLON Consortium, Moreno V, Castells A, Carracedo Á, Castellvi-Bel S, Ruiz-Ponte C. A colorectal cancer genome-wide association study in a Spanish cohort identifies two variants associated with colorectal cancer risk at 1p33 and 8p12 BMC Genomics 2013, 14: 55. PMID: 23350875, PMCID: PMC3616862, DOI: 10.1186/1471-2164-14-55.
  • Risk of Cancer in Cases of Suspected Lynch Syndrome Without Germline MutationRodríguez–Soler M, Pérez–Carbonell L, Guarinos C, Zapater P, Castillejo A, Barberá VM, Juárez M, Bessa X, Xicola RM, Clofent J, Bujanda L, Balaguer F, Reñé J, de–Castro L, Marín–Gabriel J, Lanas A, Cubiella J, Nicolás–Pérez D, Brea–Fernández A, Castellví–Bel S, Alenda C, Ruiz–Ponte C, Carracedo A, Castells A, Andreu M, Llor X, Soto JL, Payá A, Jover R. Risk of Cancer in Cases of Suspected Lynch Syndrome Without Germline Mutation Gastroenterology 2013, 144: 926-932.e1. PMID: 23354017, DOI: 10.1053/j.gastro.2013.01.044.
  • BMP2 / BMP4 colorectal cancer susceptibility loci in northern and southern European populationsFernandez-Rozadilla C, Palles C, Carvajal-Carmona L, Peterlongo P, Nici C, Veneroni S, Pinheiro M, Teixeira MR, Moreno V, Lamas MJ, Baiget M, Lopez-Fernandez L, Gonzalez D, Brea-Fernandez A, Clofent J, Bujanda L, Bessa X, Andreu M, Xicola R, Llor X, Jover R, Castells A, Castellvi-Bel S, Carracedo A, Tomlinson I, Ruiz-Ponte C. BMP2 / BMP4 colorectal cancer susceptibility loci in northern and southern European populations Carcinogenesis 2012, 34: 314-318. PMID: 23161572, DOI: 10.1093/carcin/bgs357.
  • BMPR1A mutations in early‐onset colorectal cancer with mismatch repair proficiencyFernandez‐Rozadilla C, Brea‐Fernández A, Bessa X, Álvarez‐Urturi C, Abulí A, Clofent J, Payá A, Consortium T, Jover R, Xicola R, Llor X, Andreu M, Castells A, Carracedo Á, Castellví‐Bel S, Ruiz‐Ponte C. BMPR1A mutations in early‐onset colorectal cancer with mismatch repair proficiency Clinical Genetics 2012, 84: 94-96. PMID: 23057600, DOI: 10.1111/cge.12023.
  • Abstract PR02: Genetic variation in the vitamin D pathway and risk for colorectal cancer in African Americans.Pibiri F, Kittles R, Sandler R, Keku T, Kupfer S, Xicola R, Llor X, Ellis N. Abstract PR02: Genetic variation in the vitamin D pathway and risk for colorectal cancer in African Americans. Cancer Epidemiology Biomarkers & Prevention 2012, 21: pr02-pr02. DOI: 10.1158/1055-9965.disp12-pr02.
  • A High Degree of LINE-1 Hypomethylation Is a Unique Feature of Early-Onset Colorectal CancerAntelo M, Balaguer F, Shia J, Shen Y, Hur K, Moreira L, Cuatrecasas M, Bujanda L, Giraldez MD, Takahashi M, Cabanne A, Barugel ME, Arnold M, Roca EL, Andreu M, Castellvi-Bel S, Llor X, Jover R, Castells A, Boland CR, Goel A. A High Degree of LINE-1 Hypomethylation Is a Unique Feature of Early-Onset Colorectal Cancer PLOS ONE 2012, 7: e45357. PMID: 23049789, PMCID: PMC3458035, DOI: 10.1371/journal.pone.0045357.
  • Sa1774 Prevalence of MLH1 Constitutional Epimutations as a Cause of Lynch Syndrome in Unselected Consecutive Cases of Colorectal CancerRodriguez-Soler M, Pérez-Carbonell L, Guarinos C, Castillejo A, Egoavil C, Barberà V, Martinez-Dueńas E, Castillejo M, Martinez-Canto A, Sanchez-Heras A, Ruiz-Ponte C, Brea A, Alenda C, Paya A, Sanchez-Fortun C, Juarez-Quesada M, Bujanda L, Clofent J, Llor X, Andreu M, Castells A, Carracedo A, Soto J, Jover R. Sa1774 Prevalence of MLH1 Constitutional Epimutations as a Cause of Lynch Syndrome in Unselected Consecutive Cases of Colorectal Cancer Gastroenterology 2012, 142: s-322. DOI: 10.1016/s0016-5085(12)61211-6.
  • Su1813 Susceptibility Genetic Variants Associated With Early-Onset Colorectal CancerGiráldez M, López-Dóriga A, Bujanda L, Abulí A, Bessa X, Fernandez-Rozadilla C, Munoz J, Cuatrecasas M, Jover R, Xicola R, Llor X, Piqué J, Carracedo A, Ruiz-Ponte C, Cosme A, Enriquez-Navascués J, Moreno V, Andreu M, Castells A, Balaguer F, Castellvi-Bel S. Su1813 Susceptibility Genetic Variants Associated With Early-Onset Colorectal Cancer Gastroenterology 2012, 142: s-510. DOI: 10.1016/s0016-5085(12)61954-4.
  • Abstract 1653: Genetic variation in the vitamin D pathway and risk for colorectal cancer in African AmericansPibiri F, Kittles R, Sandler R, Keku T, Kupfer S, LLor X, Ellis N. Abstract 1653: Genetic variation in the vitamin D pathway and risk for colorectal cancer in African Americans Cancer Research 2012, 72: 1653-1653. DOI: 10.1158/1538-7445.am2012-1653.
  • Abstract 3597: The Chicago Colorectal Cancer Consortium (CCCC) experience: Understanding colorectal cancer disparitiesXicola R, Gagnon M, Shaw J, Rodriguez G, Pusatcioglu C, Clark J, James R, Ravella S, Guzman G, Janoski A, Morrissey M, Mraz K, Cerye K, Chaudhry V, Kupfer S, Melson J, Freeman V, Xie H, Braunchweig C, Ellis N, Llor X. Abstract 3597: The Chicago Colorectal Cancer Consortium (CCCC) experience: Understanding colorectal cancer disparities Cancer Research 2012, 72: 3597-3597. DOI: 10.1158/1538-7445.am2012-3597.
  • Defectos de la metilación del ADN en el cáncer colorrectal esporádico y hereditarioXicola RM, Llor X. Defectos de la metilación del ADN en el cáncer colorrectal esporádico y hereditario Gastroenterología Y Hepatología 2012, 35: 480-487. PMID: 22459641, DOI: 10.1016/j.gastrohep.2012.01.010.
  • Pharmacogenomics in colorectal cancer: a genome-wide association study to predict toxicity after 5-fluorouracil or FOLFOX administrationFernandez-Rozadilla C, Cazier JB, Moreno V, Crous-Bou M, Guinó E, Durán G, Lamas MJ, López R, Candamio S, Gallardo E, Paré L, Baiget M, Páez D, López-Fernández LA, Cortejoso L, García MI, Bujanda L, González D, Gonzalo V, Rodrigo L, Reñé JM, Jover R, Brea-Fernández A, Andreu M, Bessa X, Llor X, Xicola R, Palles C, Tomlinson I, Castellví-Bel S, Castells A, Ruiz-Ponte C, Carracedo A. Pharmacogenomics in colorectal cancer: a genome-wide association study to predict toxicity after 5-fluorouracil or FOLFOX administration The Pharmacogenomics Journal 2012, 13: 209-217. PMID: 22310351, DOI: 10.1038/tpj.2012.2.
  • Seeking genetic susceptibility variants for colorectal cancer: the EPICOLON consortium experienceCastellví-Bel S, Ruiz-Ponte C, Fernández-Rozadilla C, Abulí A, Muñoz J, Bessa X, Brea-Fernández A, Ferro M, Giráldez MD, Xicola RM, Llor X, Jover R, Piqué JM, Andreu M, Castells A, Carracedo A. Seeking genetic susceptibility variants for colorectal cancer: the EPICOLON consortium experience Mutagenesis 2012, 27: 153-159. PMID: 22294762, DOI: 10.1093/mutage/ger047.
  • Susceptibility genetic variants associated with early-onset colorectal cancerGiráldez MD, López-Dóriga A, Bujanda L, Abulí A, Bessa X, Fernández-Rozadilla C, Muñoz J, Cuatrecasas M, Jover R, Xicola RM, Llor X, Piqué JM, Carracedo A, Ruiz-Ponte C, Cosme A, Enríquez-Navascués JM, Moreno V, Andreu M, Castells A, Balaguer F, Castellví-Bel S. Susceptibility genetic variants associated with early-onset colorectal cancer Carcinogenesis 2012, 33: 613-619. PMID: 22235025, DOI: 10.1093/carcin/bgs009.
  • When Should We Suspect Hereditary Colorectal Cancer Syndrome?Llor X. When Should We Suspect Hereditary Colorectal Cancer Syndrome? Clinical Gastroenterology And Hepatology 2011, 10: 363-367. PMID: 22178459, DOI: 10.1016/j.cgh.2011.12.022.
  • Colorectal Cancers with Microsatellite Instability Display Unique miRNA ProfilesBalaguer F, Moreira L, Lozano JJ, Link A, Ramirez G, Shen Y, Cuatrecasas M, Arnold M, Meltzer SJ, Syngal S, Stoffel E, Jover R, Llor X, Castells A, Boland CR, Gironella M, Goel A. Colorectal Cancers with Microsatellite Instability Display Unique miRNA Profiles Clinical Cancer Research 2011, 17: 6239-6249. PMID: 21844009, PMCID: PMC3186834, DOI: 10.1158/1078-0432.ccr-11-1424.
  • Stool-fermented Plantago ovata husk induces apoptosis in colorectal cancer cells independently of molecular phenotypeSohn VR, Giros A, Xicola RM, Fluvià L, Grzybowski M, Anguera A, Llor X. Stool-fermented Plantago ovata husk induces apoptosis in colorectal cancer cells independently of molecular phenotype British Journal Of Nutrition 2011, 107: 1591-1602. PMID: 22018732, DOI: 10.1017/s0007114511004910.
  • Comparison between universal molecular screening for Lynch syndrome and revised Bethesda guidelines in a large population-based cohort of patients with colorectal cancerPérez-Carbonell L, Ruiz-Ponte C, Guarinos C, Alenda C, Payá A, Brea A, Egoavil CM, Castillejo A, Barberá VM, Bessa X, Xicola RM, Rodríguez-Soler M, Sánchez-Fortún C, Acame N, Castellví-Bel S, Piñol V, Balaguer F, Bujanda L, De-Castro ML, Llor X, Andreu M, Carracedo A, Soto JL, Castells A, Jover R. Comparison between universal molecular screening for Lynch syndrome and revised Bethesda guidelines in a large population-based cohort of patients with colorectal cancer Gut 2011, 61: 865. PMID: 21868491, DOI: 10.1136/gutjnl-2011-300041.
  • Case-control study for colorectal cancer genetic susceptibility in EPICOLON: previously identified variants and mucinsAbulí A, Fernández-Rozadilla C, Alonso-Espinaco V, Muñoz J, Gonzalo V, Bessa X, González D, Clofent J, Cubiella J, Morillas JD, Rigau J, Latorre M, Fernández-Bañares F, Peña E, Riestra S, Payá A, Jover R, Xicola RM, Llor X, Carvajal-Carmona L, Villanueva CM, Moreno V, Piqué JM, Carracedo A, Castells A, Andreu M, Ruiz-Ponte C, Castellví-Bel S, for the Gastrointestinal Oncology Group of the Spanish Gastroenterological Association. Case-control study for colorectal cancer genetic susceptibility in EPICOLON: previously identified variants and mucins BMC Cancer 2011, 11: 339. PMID: 21819567, PMCID: PMC3176240, DOI: 10.1186/1471-2407-11-339.
  • A two-phase case–control study for colorectal cancer genetic susceptibility: candidate genes from chromosomal regions 9q22 and 3q22Abulí A, Fernández-Rozadilla C, Giráldez MD, Muñoz J, Gonzalo V, Bessa X, Bujanda L, Reñé JM, Lanas A, García AM, Saló J, Argüello L, Vilella À, Carreño R, Jover R, Xicola RM, Llor X, Carvajal-Carmona L, Tomlinson IP, Kerr DJ, Houlston RS, Piqué JM, Carracedo A, Castells A, Andreu M, Ruiz-Ponte C, Castellví-Bel S, for the Gastrointestinal Oncology Group of the Spanish Gastroenterological Association. A two-phase case–control study for colorectal cancer genetic susceptibility: candidate genes from chromosomal regions 9q22 and 3q22 British Journal Of Cancer 2011, 105: 870-875. PMID: 21811255, PMCID: PMC3171011, DOI: 10.1038/bjc.2011.296.
  • Validation Microsatellite Path Score in a Population-Based Cohort of Patients With Colorectal CancerBessa X, Alenda C, Paya A, Álvarez C, Iglesias M, Seoane A, Dedeu JM, Abulí A, Ilzarbe L, Navarro G, Pellise M, Balaguer F, Castellvi-Bel S, LLor X, Castells A, Jover R, Andreu M. Validation Microsatellite Path Score in a Population-Based Cohort of Patients With Colorectal Cancer Journal Of Clinical Oncology 2011, 29: 3374-3380. PMID: 21788563, DOI: 10.1200/jco.2010.34.3947.
  • Cancer Risk Assessment in Lynch Syndrome: Does the Gene Matter?Xicola RM, Llor X. Cancer Risk Assessment in Lynch Syndrome: Does the Gene Matter? JAMA 2011, 305: 2351-2352. PMID: 21642691, DOI: 10.1001/jama.2011.771.
  • Comparison Between Universal Immunohistochemistry for Mismatch Repair Proteins Versus Revised Bethesda Guidelines in the Detection of Patients With Lynch SyndromePérez-Carbonell L, Guarinos C, Soler M, Sanchez-Fortun C, Sempere-Robles L, Ruiz-Ponte C, Castillejo A, Brea A, Carracedo A, Barberá V, Rojas E, Bujanda L, Clofent J, Andreu M, Llor X, Castells A, Soto J, Jover R. Comparison Between Universal Immunohistochemistry for Mismatch Repair Proteins Versus Revised Bethesda Guidelines in the Detection of Patients With Lynch Syndrome Gastroenterology 2011, 140: s-97. DOI: 10.1016/s0016-5085(11)60394-6.
  • Differential Features of Colorectal Cancer (CRC) in Patients With Probable Non-Sporadic Mismatch Repair Deficiency Without Germline MutationSoler M, Pérez-Carbonell L, Guarinos C, Ruiz-Ponte C, Brea A, Castillejo A, Barberá V, Sanchez-Fortun C, Sempere-Robles L, Bujanda L, Clofent J, Llor X, Andreu M, Castells A, Carracedo A, Soto J, Payá A, Alenda C, Jover R. Differential Features of Colorectal Cancer (CRC) in Patients With Probable Non-Sporadic Mismatch Repair Deficiency Without Germline Mutation Gastroenterology 2011, 140: s-190-s-191. DOI: 10.1016/s0016-5085(11)60767-1.
  • Identification of a Chromosome 10 Region Potentially Implicated in Hereditary Non-Polyposis Colorectal Cancer Without Mismatch Repair MutationsXicola R, Below J, Doyle B, Garre P, Zhang W, Caldes T, Cox N, Llor X. Identification of a Chromosome 10 Region Potentially Implicated in Hereditary Non-Polyposis Colorectal Cancer Without Mismatch Repair Mutations Gastroenterology 2011, 140: s-97. DOI: 10.1016/s0016-5085(11)60395-8.
  • Identification of Mirnas and Their Gene Targets Differentially Expressed in Microsatellite Stable and Unstable Colorectal Cancers Through an Integrated AnalysisXicola R, Mu W, Huang L, Sohn V, Doyle B, Jover R, Carracedo A, Andreu M, Bessa X, Castells A, Boland C, Goel A, Investigators E, Dai Y, Llor X. Identification of Mirnas and Their Gene Targets Differentially Expressed in Microsatellite Stable and Unstable Colorectal Cancers Through an Integrated Analysis Gastroenterology 2011, 140: s-819. DOI: 10.1016/s0016-5085(11)63391-x.
  • Increased Line-1 Hypomethylation is a Unique Feature of Early-Onset Colorectal Cancer (CRC)Balaguer F, Antelo M, Shen Y, Hur K, Giraldez M, Bujanda L, Takahashi M, Cabanne A, Barugel M, Arnold M, Roca E, Andreu M, Llor X, Jover R, Castells A, Boland C, Goel A. Increased Line-1 Hypomethylation is a Unique Feature of Early-Onset Colorectal Cancer (CRC) Gastroenterology 2011, 140: s-820-s-821. DOI: 10.1016/s0016-5085(11)63397-0.
  • Analysis of the Oxidative Damage Repair Genes NUDT1, OGG1, and MUTYH in Patients from Mismatch Repair Proficient HNPCC Families (MSS-HNPCC)Garre P, Briceño V, Xicola RM, Doyle BJ, de la Hoya M, Sanz J, Llovet P, Pescador P, Puente J, Díaz-Rubio E, Llor X, Caldés T. Analysis of the Oxidative Damage Repair Genes NUDT1, OGG1, and MUTYH in Patients from Mismatch Repair Proficient HNPCC Families (MSS-HNPCC) Clinical Cancer Research 2011, 17: 1701-1712. PMID: 21355073, DOI: 10.1158/1078-0432.ccr-10-2491.
  • Evidence for classification of c.1852_1853AA>GC in MLH1 as a neutral variant for Lynch syndromeCastillejo A, Guarinos C, Martinez-Canto A, Barbera VM, Egoavil C, Castillejo MI, Perez-Carbonell L, Sanchez-Heras AB, Segura A, Ochoa E, Lazaro R, Ruiz-Ponte C, Bujanda L, Andreu M, Castells A, Carracedo A, Llor X, Clofent J, Alenda C, Paya A, Jover R, Soto JL. Evidence for classification of c.1852_1853AA>GC in MLH1 as a neutral variant for Lynch syndrome BMC Medical Genomics 2011, 12: 12. PMID: 21247423, PMCID: PMC3034663, DOI: 10.1186/1471-2350-12-12.
  • 5-Fluorouracil Adjuvant Chemotherapy Does Not Increase Survival in Patients With CpG Island Methylator Phenotype Colorectal CancerJover R, Nguyen T, Pérez–Carbonell L, Zapater P, Payá A, Alenda C, Rojas E, Cubiella J, Balaguer F, Morillas JD, Clofent J, Bujanda L, Reñé JM, Bessa X, Xicola RM, Nicolás–Pérez D, Castells A, Andreu M, Llor X, Boland CR, Goel A. 5-Fluorouracil Adjuvant Chemotherapy Does Not Increase Survival in Patients With CpG Island Methylator Phenotype Colorectal Cancer Gastroenterology 2010, 140: 1174-1181. PMID: 21185836, PMCID: PMC3073650, DOI: 10.1053/j.gastro.2010.12.035.
  • Single Nucleotide Polymorphisms in the Wnt and BMP Pathways and Colorectal Cancer Risk in a Spanish CohortFernández-Rozadilla C, de Castro L, Clofent J, Brea-Fernández A, Bessa X, Abulí A, Andreu M, Jover R, Xicola R, Llor X, Castells A, Castellví-Bel S, Carracedo A, Ruiz-Ponte C, . Single Nucleotide Polymorphisms in the Wnt and BMP Pathways and Colorectal Cancer Risk in a Spanish Cohort PLOS ONE 2010, 5: e12673. PMID: 20844743, PMCID: PMC2936577, DOI: 10.1371/journal.pone.0012673.
  • Susceptibility Genetic Variants Associated With Colorectal Cancer Risk Correlate With Cancer PhenotypeAbulí A, Bessa X, González JR, Ruiz–Ponte C, Cáceres A, Muñoz J, Gonzalo V, Balaguer F, Fernández–Rozadilla C, González D, de Castro L, Clofent J, Bujanda L, Cubiella J, Reñé J, Morillas JD, Lanas Á, Rigau J, García A, Latorre M, Saló J, Bañares F, Argüello L, Peña E, Vilella À, Riestra S, Carreño R, Paya A, Alenda C, Xicola RM, Doyle BJ, Jover R, Llor X, Carracedo A, Castells A, Castellví–Bel S, Andreu M, Association G. Susceptibility Genetic Variants Associated With Colorectal Cancer Risk Correlate With Cancer Phenotype Gastroenterology 2010, 139: 788-796.e6. PMID: 20638935, DOI: 10.1053/j.gastro.2010.05.072.
  • Methylation Analysis of MLH1 Improves the Selection of Patients for Genetic Testing in Lynch SyndromePérez-Carbonell L, Alenda C, Payá A, Castillejo A, Barberá VM, Guillén C, Rojas E, Acame N, Gutiérrez-Aviñó FJ, Castells A, Llor X, Andreu M, Soto JL, Jover R. Methylation Analysis of MLH1 Improves the Selection of Patients for Genetic Testing in Lynch Syndrome Journal Of Molecular Diagnostics 2010, 12: 498-504. PMID: 20489114, PMCID: PMC2893635, DOI: 10.2353/jmoldx.2010.090212.
  • S1993 Comparison Between Routine Immunohistochemistry for Mismatch Repair Proteins Versus Revised Bethesda Guidelines in the Diagnosis of Lynch Syndrome in a Non-Selected Population of Colorectal Cancer PatientsPérez-Carbonell L, Ruiz-Ponte C, Bessa X, Soto J, Castillejo A, Barberá V, Brea A, Sempere L, Sánchez-Fortún C, Castellvi-Bel S, Balaguer F, Xicola R, Llor X, Abulí A, Andreu M, Alenda C, Payá A, Carracedo A, Castells A, Jover R. S1993 Comparison Between Routine Immunohistochemistry for Mismatch Repair Proteins Versus Revised Bethesda Guidelines in the Diagnosis of Lynch Syndrome in a Non-Selected Population of Colorectal Cancer Patients Gastroenterology 2010, 138: s-297. DOI: 10.1016/s0016-5085(10)61364-9.
  • S1984 Case-Control Genetic Association Study of Candidates Genes for Genetic Susceptibility to Colorectal CancerAbulí A, Fernandez-Rozadilla C, Alonso-Espinaco V, Giráldez M, Muñoz J, Bessa X, Llor X, Jover R, Carvajal-Carmona L, Tomlinson I, Moreno V, Carracedo A, Castells A, Andreu M, Ruiz-Ponte C, Castellvi-Bel S. S1984 Case-Control Genetic Association Study of Candidates Genes for Genetic Susceptibility to Colorectal Cancer Gastroenterology 2010, 138: s-295. DOI: 10.1016/s0016-5085(10)61355-8.
  • 745 Colorectal Cancers (CRCs) With the CpG Island Methylator Phenotype (CIMP) Do Not Show Improved Survival With 5-Fluorouracil (5FU)-Based Adjuvant ChemotherapyJover R, Nguyen T, Pérez-Carbonell L, Payá A, Alenda C, Rojas E, Castells A, Andreu M, Llor X, Boland C, Goel A. 745 Colorectal Cancers (CRCs) With the CpG Island Methylator Phenotype (CIMP) Do Not Show Improved Survival With 5-Fluorouracil (5FU)-Based Adjuvant Chemotherapy Gastroenterology 2010, 138: s-102. DOI: 10.1016/s0016-5085(10)60466-0.
  • T1710 MicroRNA Expression Profiles Distinguish Various Molecular Subtypes of Colorectal Cancer (CRC)Balaguer F, Moreira L, Lozano J, Link A, Ramirez G, Cuatrecasas M, Arnold M, Stoffel E, Syngal S, Jover R, Llor X, Castells A, Boland C, Gironella M, Goel A. T1710 MicroRNA Expression Profiles Distinguish Various Molecular Subtypes of Colorectal Cancer (CRC) Gastroenterology 2010, 138: s-562-s-563. DOI: 10.1016/s0016-5085(10)62588-7.
  • S1994 Base Excision Repair Genes MYH, Ogg1 and Nudt1 and Mismatch Repair Gene Variants in Hereditary Non-Polyposis Colorectal Cancer Without Mismatch Repair Deficiency (MSS HNPCC)Xicola R, Garre P, Doyle B, Bandipalliam P, Sapoznik V, Syngal S, Castells A, Jover R, Andreu M, Boland C, Goel A, Caldes T, Llor X. S1994 Base Excision Repair Genes MYH, Ogg1 and Nudt1 and Mismatch Repair Gene Variants in Hereditary Non-Polyposis Colorectal Cancer Without Mismatch Repair Deficiency (MSS HNPCC) Gastroenterology 2010, 138: s-297. DOI: 10.1016/s0016-5085(10)61365-0.
  • Colorectal cancer prognosis twenty years later.Bujanda L, Sarasqueta C, Hijona E, Hijona L, Cosme A, Gil I, Elorza JL, Asensio JI, Larburu S, Enríquez-Navascués JM, Jover R, Balaguer F, Llor X, Bessa X, Andreu M, Paya A, Castells A. Colorectal cancer prognosis twenty years later. World Journal Of Gastroenterology 2010, 16: 862-7. PMID: 20143465, PMCID: PMC2825333, DOI: 10.3748/wjg.v16.i7.862.
  • Colorectal Cancer Susceptibility Quantitative Trait Loci in Mice as a Novel Approach to Detect Low-Penetrance Variants in Humans: A Two-Stage Case-Control StudyFernández-Rozadilla C, Tarrío R, Clofent J, de Castro L, Brea-Fernández A, Bessa X, Abulí A, Andreu M, Jover R, Xicola R, Llor X, Castells A, Castellví-Bel S, Carracedo A, Ruiz-Ponte C, Association F. Colorectal Cancer Susceptibility Quantitative Trait Loci in Mice as a Novel Approach to Detect Low-Penetrance Variants in Humans: A Two-Stage Case-Control Study Cancer Epidemiology Biomarkers & Prevention 2010, 19: 619-623. PMID: 20142256, DOI: 10.1158/1055-9965.epi-09-1175.
  • Aberrant DNA Methylation in Hereditary Nonpolyposis Colorectal Cancer Without Mismatch Repair DeficiencyGoel A, Xicola RM, Nguyen T, Doyle BJ, Sohn VR, Bandipalliam P, Rozek LS, Reyes J, Cordero C, Balaguer F, Castells A, Jover R, Andreu M, Syngal S, Boland CR, Llor X. Aberrant DNA Methylation in Hereditary Nonpolyposis Colorectal Cancer Without Mismatch Repair Deficiency Gastroenterology 2010, 138: 1854-1862.e1. PMID: 20102720, PMCID: PMC2859993, DOI: 10.1053/j.gastro.2010.01.035.
  • Aberrant Gene Promoter Methylation Associated with Sporadic Multiple Colorectal CancerGonzalo V, Lozano JJ, Muñoz J, Balaguer F, Pellisé M, de Miguel C, Andreu M, Jover R, Llor X, Giráldez MD, Ocaña T, Serradesanferm A, Alonso-Espinaco V, Jimeno M, Cuatrecasas M, Sendino O, Castellví-Bel S, Castells A, . Aberrant Gene Promoter Methylation Associated with Sporadic Multiple Colorectal Cancer PLOS ONE 2010, 5: e8777. PMID: 20098741, PMCID: PMC2808250, DOI: 10.1371/journal.pone.0008777.
  • Association of MUTYH and MSH6 germline mutations in colorectal cancer patientsGiráldez MD, Balaguer F, Caldés T, Sanchez-de-Abajo A, Gómez-Fernández N, Ruiz-Ponte C, Muñoz J, Garre P, Gonzalo V, Moreira L, Ocaña T, Clofent J, Carracedo A, Andreu M, Jover R, Llor X, Castells A, Castellví-Bel S, Gastrointestinal Oncology Group of the Spanish Gastroenterological Association. Association of MUTYH and MSH6 germline mutations in colorectal cancer patients Familial Cancer 2009, 8: 525. PMID: 19685280, DOI: 10.1007/s10689-009-9282-4.
  • Regulation of Colorectal Cancer Cell Apoptosis by the n-3 Polyunsaturated Fatty Acids Docosahexaenoic and EicosapentaenoicGiros A, Grzybowski M, Sohn VR, Pons E, Fernandez-Morales J, Xicola RM, Sethi P, Grzybowski J, Goel A, Boland CR, Gassull MA, Llor X. Regulation of Colorectal Cancer Cell Apoptosis by the n-3 Polyunsaturated Fatty Acids Docosahexaenoic and Eicosapentaenoic Cancer Prevention Research 2009, 2: 732-742. PMID: 19638488, PMCID: PMC3793343, DOI: 10.1158/1940-6207.capr-08-0197.
  • M1930 Identification of Genomic Variants in Hereditary Non-Polyposis Colorectal Cancer Without Mismatch Repair Deficiency (MSS HNPCC)Xicola R, Caldes T, Garre P, Doyle B, Bandipalliam P, Syngal S, Grzybowski J, Sapoznik V, Grzybowski M, Martinez T, Murugappan S, Castells A, Jover R, Andreu M, Goel A, Llor X. M1930 Identification of Genomic Variants in Hereditary Non-Polyposis Colorectal Cancer Without Mismatch Repair Deficiency (MSS HNPCC) Gastroenterology 2009, 136: a-449. DOI: 10.1016/s0016-5085(09)62065-5.
  • 198 CpG-Island Methylator Phenotype (CIMP) and Alterations in RAS-Raf Signaling in Hereditary Non-Polyposis Colorectal Cancers Without Mismatch Repair Deficiency (MSS HNPCC)Xicola R, Nguyen T, Doyle B, Bandipalliam P, Syngal S, Reyes J, Cordero C, Grzybowski J, Sapoznik V, Grzybowski M, Castells A, Jover R, Andreu M, Boland C, Llor X, Goel A. 198 CpG-Island Methylator Phenotype (CIMP) and Alterations in RAS-Raf Signaling in Hereditary Non-Polyposis Colorectal Cancers Without Mismatch Repair Deficiency (MSS HNPCC) Gastroenterology 2009, 136: a-37. DOI: 10.1016/s0016-5085(09)60169-4.
  • 767 Genotype-Phenotype Correlation of Genetic Susceptibility Variants Identified Through Genome-Wide Association Studies for Colorectal CancerAbulí A, Bessa X, Ruiz-Ponte C, Fernandez-Rozadilla C, Carracedo A, Ilzarbe L, Llor X, Jover R, Muñoz J, Castells A, Castellvi-Bel S, Andreu M. 767 Genotype-Phenotype Correlation of Genetic Susceptibility Variants Identified Through Genome-Wide Association Studies for Colorectal Cancer Gastroenterology 2009, 136: a-120. DOI: 10.1016/s0016-5085(09)60537-0.
  • M1953 Frequency and Characteristics of Hereditary Non-Polyposis Colorectal Cancer (HNPCC) and Other Non-Syndromic Colorectal Cancer (CRC) Familial Forms in Spain. Preliminary Data of a Prospective, Multicenter, Population-Based Study (Epicolon-II)Bessa X, Gonzalez D, Roman E, Bujanda L, Enriquez-Navascués J, Reñe J, Gonzalo V, Jover R, Llor X, Peña E, Latorre M, de Castro Parga M, Carracedo A, Castells A, Andreu M. M1953 Frequency and Characteristics of Hereditary Non-Polyposis Colorectal Cancer (HNPCC) and Other Non-Syndromic Colorectal Cancer (CRC) Familial Forms in Spain. Preliminary Data of a Prospective, Multicenter, Population-Based Study (Epicolon-II) Gastroenterology 2009, 136: a-454. DOI: 10.1016/s0016-5085(09)62088-6.
  • W1975 African Americans Fail to Undergo Screening for Colorectal Cancer Independently of Insurance or Self-Reported IncomeKim J, Ewing R, Llor X, Carroll R, Benya R. W1975 African Americans Fail to Undergo Screening for Colorectal Cancer Independently of Insurance or Self-Reported Income Gastroenterology 2009, 136: a-765. DOI: 10.1016/s0016-5085(09)63533-2.
  • S1271 Plantago Ovata Husk Regulates Cell Cycle Progression and Wnt Signaling Pathway, Crucial Elements Implicated in Colorectal CarcinogenesisSapoznik V, Grzybowski M, Xicola R, Doyle B, Grzybowski J, Martinez T, Anguera A, Llor X. S1271 Plantago Ovata Husk Regulates Cell Cycle Progression and Wnt Signaling Pathway, Crucial Elements Implicated in Colorectal Carcinogenesis Gastroenterology 2009, 136: a-226. DOI: 10.1016/s0016-5085(09)61020-9.
  • W1891 Smoking Promotes the Formation of Hyperplastic, But Not Adenomatous, PolypsKim J, Ewing R, Llor X, Carroll R, Benya R. W1891 Smoking Promotes the Formation of Hyperplastic, But Not Adenomatous, Polyps Gastroenterology 2009, 136: a-748. DOI: 10.1016/s0016-5085(09)63450-8.
  • S1272 Differential Regulation of Apoptosis Induction By Plantago Ovata Husk in Colorectal Cancer Cells. Induction of the TNF-Alpha Apoptosis Cascade in Metastatic CellsGrzybowski M, Sapoznik V, Xicola R, Doyle B, Grzybowski J, Martinez T, Anguera A, Llor X. S1272 Differential Regulation of Apoptosis Induction By Plantago Ovata Husk in Colorectal Cancer Cells. Induction of the TNF-Alpha Apoptosis Cascade in Metastatic Cells Gastroenterology 2009, 136: a-226. DOI: 10.1016/s0016-5085(09)61021-0.
  • Utility of p16 Immunohistochemistry for the Identification of Lynch SyndromePayá A, Alenda C, Pérez-Carbonell L, Rojas E, Soto J, Guillén C, Castillejo A, Barberá V, Carrato A, Castells A, Llor X, Andreu M, Koh J, Enders GH, Benlloch S, Jover R. Utility of p16 Immunohistochemistry for the Identification of Lynch Syndrome Clinical Cancer Research 2009, 15: 3156-3162. PMID: 19383812, PMCID: PMC2825754, DOI: 10.1158/1078-0432.ccr-08-3116.
  • CORRELACIÓN GENOTIPO-FENOTIP EN EL CÁNCER COLORRECTAL EN RELACIÓN A VARIANTES GENÉTICAS DE SUSCEPTIBILIDADAbulí A, Bessa X, Ruiz-Ponte C, Fernández-Gómez C, Carracedo A, Ilzarbe L, Llor X, Jover R, Muñoz J, Castells A, Castellví-Bel S, Andreu M, Gastroenterología G. CORRELACIÓN GENOTIPO-FENOTIP EN EL CÁNCER COLORRECTAL EN RELACIÓN A VARIANTES GENÉTICAS DE SUSCEPTIBILIDAD Gastroenterología Y Hepatología 2009, 32: 181-182. DOI: 10.1016/j.gastrohep.2009.01.006.
  • EVOLUCIÓN DEL PRONÓSTICO DEL CÁNCER DE COLON EN LOS ÚLTIMOS 20 AÑOSBujanda L, Sarasqueta C, Beraza M, Hijona L, Cosme A, Elorza J, Jover R, Balaguer F, Llor X, Andreu M, Bessa X, Paya A, Castells A, Gastroenterología G. EVOLUCIÓN DEL PRONÓSTICO DEL CÁNCER DE COLON EN LOS ÚLTIMOS 20 AÑOS Gastroenterología Y Hepatología 2009, 32: 232. DOI: 10.1016/j.gastrohep.2009.01.116.
  • FRECUENCIA Y CARACTERÍSTICAS DEL CÁNCER COLORRECTAL HEREDITARIO NO POLIPOSIS (CCHNP) Y OTROS CÁNCERES COLORRECTALES NO SINDRÓMICOS EN ESPAÑA. DATOS PRELIMINARES DE UN ESTUDIO POBLACIONAL, PROSPECTIVO Y MULTICÉNTRICO (EPICOLON-II)Bessa X, Gonzalez D, Roman E, Bujanda L, Enriquez-Navascués J, Reñe J, Gonzalo V, Jover R, Xicolà R, Llor X, Peña E, Latorre M, De Castro L, Carracedo A, Castells A, Andreu M, del Grupo de Oncología E. FRECUENCIA Y CARACTERÍSTICAS DEL CÁNCER COLORRECTAL HEREDITARIO NO POLIPOSIS (CCHNP) Y OTROS CÁNCERES COLORRECTALES NO SINDRÓMICOS EN ESPAÑA. DATOS PRELIMINARES DE UN ESTUDIO POBLACIONAL, PROSPECTIVO Y MULTICÉNTRICO (EPICOLON-II) Gastroenterología Y Hepatología 2009, 32: 232-233. DOI: 10.1016/j.gastrohep.2009.01.118.
  • Extent of prevalence and size of flat neoplasms in a heterogeneous population undergoing routine colorectal cancer screeningKim J, Rami P, O’Toole J, Llor X, Carroll RE, Benya RV. Extent of prevalence and size of flat neoplasms in a heterogeneous population undergoing routine colorectal cancer screening Colorectal Disease 2009, 12: 471-476. PMID: 19298579, DOI: 10.1111/j.1463-1318.2009.01822.x.
  • "What the Primary Care Provider Needs to Know About Hereditary Colorectal Cancer"J Clin Outcomes Manage,16(12):1-9
  • "Hereditary Colorectal Cancer"Colorectal Cancer: Early detection and prevention. Editor: Kim, K. Slack Inc. New Jersey. 2009: pp. 149-166
  • The efficacy of adjuvant chemotherapy with 5-fluorouracil in colorectal cancer depends on the mismatch repair statusJover R, Zapater P, Castells A, Llor X, Andreu M, Cubiella J, Balaguer F, Sempere L, Xicola RM, Bujanda L, Reñé JM, Clofent J, Bessa X, Morillas JD, Nicolás-Pérez D, Pons E, Payá A, Alenda C, Association G. The efficacy of adjuvant chemotherapy with 5-fluorouracil in colorectal cancer depends on the mismatch repair status European Journal Of Cancer 2008, 45: 365-373. PMID: 18722765, DOI: 10.1016/j.ejca.2008.07.016.
  • Comparison of predictive models, clinical criteria and molecular tumour screening for the identification of patients with Lynch syndrome in a population-based cohort of colorectal cancer patientsBalmaña J, Balaguer F, Castellví-Bel S, Steyerberg EW, Andreu M, Llor X, Jover R, Castells A, Syngal S. Comparison of predictive models, clinical criteria and molecular tumour screening for the identification of patients with Lynch syndrome in a population-based cohort of colorectal cancer patients Journal Of Medical Genetics 2008, 45: 557. PMID: 18603628, DOI: 10.1136/jmg.2008.059311.
  • Aberrant Crypt Focus Size Predicts Distal Polyp HistopathologyKim J, Ng J, Arozulllah A, Ewing R, Llor X, Carroll RE, Benya RV. Aberrant Crypt Focus Size Predicts Distal Polyp Histopathology Cancer Epidemiology Biomarkers & Prevention 2008, 17: 1155-1162. PMID: 18483337, DOI: 10.1158/1055-9965.epi-07-2731.
  • M2051 Genome-Wide Expression Profiling Reveals a Common Biomarker Gene Signature in ColitisMontero T, Llor X, Gil A, Gassull M, Suarez A. M2051 Genome-Wide Expression Profiling Reveals a Common Biomarker Gene Signature in Colitis Gastroenterology 2008, 134: a-458-a-459. DOI: 10.1016/s0016-5085(08)62144-7.
  • T2027 Comparison of Predictive Models and Clinical Criteria for the Identification of Patients with Lynch Syndrome in a Population-Based Cohort of Colorectal Cancer (CRC) PatientsBalmaña J, Balaguer F, Castellvi-Bel S, Steyerberg E, Andreu M, Llor X, Jover R, Castells A, Syngal S. T2027 Comparison of Predictive Models and Clinical Criteria for the Identification of Patients with Lynch Syndrome in a Population-Based Cohort of Colorectal Cancer (CRC) Patients Gastroenterology 2008, 134: a-603. DOI: 10.1016/s0016-5085(08)62817-6.
  • M1636 Gene-Expression Signature-Based Approach Identifies Pro-Apoptotic Compounds in CACO-2 Cell LineMontero T, Llor X, Suarez A. M1636 Gene-Expression Signature-Based Approach Identifies Pro-Apoptotic Compounds in CACO-2 Cell Line Gastroenterology 2008, 134: a-387. DOI: 10.1016/s0016-5085(08)61806-5.
  • 151 Docosahexaenoic and Eicosahexaenoic N-3 Fatty Acids Inhibit DNA Synthesis and Cell Proliferation in Colorectal Cancer Cells Independent of the Responsible Underlying Molecular PathwaysGiros A, Sapoznik V, Fernandez-Morales J, Xicola R, Llor X. 151 Docosahexaenoic and Eicosahexaenoic N-3 Fatty Acids Inhibit DNA Synthesis and Cell Proliferation in Colorectal Cancer Cells Independent of the Responsible Underlying Molecular Pathways Gastroenterology 2008, 134: a-27. DOI: 10.1016/s0016-5085(08)60133-x.
  • T1093 Aberrant Crypt Focus Size Predicts Distal Polyp HistopathologyKim J, Ewing R, Carroll R, Llor X, Benya R. T1093 Aberrant Crypt Focus Size Predicts Distal Polyp Histopathology Gastroenterology 2008, 134: a-482. DOI: 10.1016/s0016-5085(08)62254-4.
  • S2007 Bacterial Microbiota Fingerprints Are Altered in Colon CancerMutlu E, Glover S, Gillevet P, Llor X, Quander C, Sikaroodi M, Engen P, Bracamonte S, Keshavarzian A. S2007 Bacterial Microbiota Fingerprints Are Altered in Colon Cancer Gastroenterology 2008, 134: a-296. DOI: 10.1016/s0016-5085(08)61377-3.
  • A Prospective, Multicenter, Population-Based Study of BRAF Mutational Analysis for Lynch Syndrome ScreeningBessa X, Ballesté B, Andreu M, Castells A, Bellosillo B, Balaguer F, Castellví–bel S, Paya A, Jover R, Alenda C, Titó L, Martinez–Villacampa M, Vilella A, Xicola RM, Pons E, Llor X, Association G. A Prospective, Multicenter, Population-Based Study of BRAF Mutational Analysis for Lynch Syndrome Screening Clinical Gastroenterology And Hepatology 2007, 6: 206-214. PMID: 18096441, DOI: 10.1016/j.cgh.2007.10.011.
  • Validation and Extension of the PREMM1,2 Model in a Population-Based Cohort of Colorectal Cancer PatientsBalaguer F, Balmaña J, Castellví–Bel S, Steyerberg EW, Andreu M, Llor X, Jover R, Syngal S, Castells A, Association G. Validation and Extension of the PREMM1,2 Model in a Population-Based Cohort of Colorectal Cancer Patients Gastroenterology 2007, 134: 39-46. PMID: 18061181, PMCID: PMC2542581, DOI: 10.1053/j.gastro.2007.10.042.
  • Detection of Metachronous Neoplasms in Colorectal Cancer Patients: Identification of Risk FactorsBallesté B, Bessa X, Piñol V, CastellvíBel S, Castells A, Alenda C, Paya A, Jover R, Xicola RM, Pons E, Llor X, Cordero C, FernandezBañares F, de Castro L, Reñé JM, Andreu M. Detection of Metachronous Neoplasms in Colorectal Cancer Patients: Identification of Risk Factors Diseases Of The Colon & Rectum 2007, 50: 971-980. PMID: 17468913, DOI: 10.1007/s10350-007-0237-2.
  • Association of the ARLTS1 Cys148Arg variant with sporadic and familial colorectal cancerCastellví-Bel S, Castells A, de Cid R, Muñoz J, Balaguer F, Gonzalo V, Ruiz-Ponte C, Andreu M, Llor X, Jover R, Bessa X, Xicola RM, Pons E, Alenda C, Payá A, Carracedo A, Piqué JM. Association of the ARLTS1 Cys148Arg variant with sporadic and familial colorectal cancer Carcinogenesis 2007, 28: 1687-1691. PMID: 17449901, DOI: 10.1093/carcin/bgm098.
  • Low adherence to colonoscopy in the screening of first-degree relatives of patients with colorectal cancerBujanda L, Sarasqueta C, Zubiaurre L, Cosme A, Muñoz C, Sánchez A, Martín C, Tito L, Piñol V, Castells A, Llor X, Xicola RM, Pons E, Clofent J, de Castro ML, Cuquerella J, Medina E, Gutierrez A, Arenas JI, Jover R. Low adherence to colonoscopy in the screening of first-degree relatives of patients with colorectal cancer Gut 2007, 56: 1714. PMID: 17400596, PMCID: PMC2095719, DOI: 10.1136/gut.2007.120709.
  • Identification of MYH Mutation Carriers in Colorectal Cancer: A Multicenter, Case-Control, Population-Based StudyBalaguer F, Castellví–Bel S, Castells A, Andreu M, Muñoz J, Gisbert JP, Llor X, Jover R, de Cid R, Gonzalo V, Bessa X, Xicola RM, Pons E, Alenda C, Payá A, Piqué JM, Association G. Identification of MYH Mutation Carriers in Colorectal Cancer: A Multicenter, Case-Control, Population-Based Study Clinical Gastroenterology And Hepatology 2007, 5: 379-387. PMID: 17368238, DOI: 10.1016/j.cgh.2006.12.025.
  • P079 IMPLICATION OF BCL-2 FAMILY PROTEINS IN THE INDUCTION OF JURKAT T LYMPHOCYTE APOPTOSIS BY THE MAIN N-3 FATTY ACIDS PRESENT IN FISH OIL DOCOSAHEXAENOIC AND EICOSAPENTAENOIC ACIDHommes T, Giros A, Llor X, Pons E, Fernandez-Morales J, Xicola R, Gassull M. P079 IMPLICATION OF BCL-2 FAMILY PROTEINS IN THE INDUCTION OF JURKAT T LYMPHOCYTE APOPTOSIS BY THE MAIN N-3 FATTY ACIDS PRESENT IN FISH OIL DOCOSAHEXAENOIC AND EICOSAPENTAENOIC ACID Journal Of Crohn's And Colitis 2007, 1: 23. DOI: 10.1016/s1873-9954(07)70091-5.
  • Performance of Different Microsatellite Marker Panels for Detection of Mismatch Repair–Deficient Colorectal TumorsXicola RM, Llor X, Pons E, Castells A, Alenda C, Piñol V, Andreu M, Castellví-Bel S, Payá A, Jover R, Bessa X, Girós A, Duque JM, Nicolás-Pérez D, Garcia AM, Rigau J, Gassull MA. Performance of Different Microsatellite Marker Panels for Detection of Mismatch Repair–Deficient Colorectal Tumors Journal Of The National Cancer Institute 2007, 99: 244-252. PMID: 17284719, DOI: 10.1093/jnci/djk033.
  • "Cancer and Inflammatory Bowel DiseasesInflammatory bowel diseases. 3rd Edition. Editors: Gassull, Gomollon, Hinojosa, Obrador. Aran Publishing. Madrid. Spain. 2007: 475-480.
  • "Inner and outer environment"Intestinal Inflammation and Colorectal Cancer. Editors: Gasche, Gassull, Herrerias Gutierrez, Monterio. Springer Science. Lancaster, UK. 2007: pp. 185-192.
  • Authors’ replyJover R, Castells A, Llor X, Andreu M. Authors’ reply Gut 2006, 55: 1819. PMID: 17124161, PMCID: PMC1856450, DOI: 10.1136/gut.2006.105627.
  • Detection of BRAF V600E Mutation in Colorectal Cancer Comparison of Automatic Sequencing and Real-Time Chemistry MethodologyBenlloch S, Payá A, Alenda C, Bessa X, Andreu M, Jover R, Castells A, Llor X, Aranda FI, Massutí B. Detection of BRAF V600E Mutation in Colorectal Cancer Comparison of Automatic Sequencing and Real-Time Chemistry Methodology Journal Of Molecular Diagnostics 2006, 8: 540-543. PMID: 17065421, PMCID: PMC1876165, DOI: 10.2353/jmoldx.2006.060070.
  • Clinical Performance of Original and Revised Bethesda Guidelines for the Identification of MSH2/MLH1 Gene Carriers in Patients with Newly Diagnosed Colorectal Cancer: Proposal of a New and Simpler Set of RecommendationsRodríguez-Moranta F, Castells A, Andreu M, Piñol V, Castellví-Bel S, Alenda C, Llor X, Xicola RM, Jover R, Payá A, Bessa X, Balaguer F, Cubiella J, Argüello L, Morillas JD, Bujanda L. Clinical Performance of Original and Revised Bethesda Guidelines for the Identification of MSH2/MLH1 Gene Carriers in Patients with Newly Diagnosed Colorectal Cancer: Proposal of a New and Simpler Set of Recommendations The American Journal Of Gastroenterology 2006, 101: ajg2006204. PMID: 16696788, DOI: 10.1111/j.1572-0241.2006.00522.x.
  • Cyclooxygenase 2 Expression in Colorectal Cancer with DNA Mismatch Repair DeficiencyCastells A, Payá A, Alenda C, Rodríguez-Moranta F, Agrelo R, Andreu M, Piñol V, Castellví-Bel S, Jover R, Llor X, Pons E, Elizalde JI, Bessa X, Alcedo J, Saló J, Medina E, Naranjo A, Esteller M, Piqué J, Association F. Cyclooxygenase 2 Expression in Colorectal Cancer with DNA Mismatch Repair Deficiency Clinical Cancer Research 2006, 12: 1686-1692. PMID: 16551850, DOI: 10.1158/1078-0432.ccr-05-1581.
  • "The Effect of Olive Oil in Inflammatory Bowel Disease"Olive Oil and Health, pp. 309-16
  • The effect of olive oil on inflammatory bowel disease.Llor X, Cabré E, Gassull M. The effect of olive oil on inflammatory bowel disease. 2006, 309-316. DOI: 10.1079/9781845930684.0309.
  • Mismatch repair status in the prediction of benefit from adjuvant fluorouracil chemotherapy in colorectal cancerJover R, Zapater P, Castells A, Llor X, Andreu M, Cubiella J, Piñol V, Xicola RM, Bujanda L, Reñé JM, Clofent J, Bessa X, Morillas JD, Nicolás-Pérez D, Payá A, Alenda C. Mismatch repair status in the prediction of benefit from adjuvant fluorouracil chemotherapy in colorectal cancer Gut 2005, 55: 848. PMID: 16299036, PMCID: PMC1856227, DOI: 10.1136/gut.2005.073015.
  • Differential Features of Colorectal Cancers Fulfilling Amsterdam Criteria without Involvement of the Mutator PathwayLlor X, Pons E, Xicola RM, Castells A, Alenda C, Piñol V, Andreu M, Castellví-Bel S, Payá A, Jover R, Bessa X, Girós A, Roca A, Gassull MA, Association F. Differential Features of Colorectal Cancers Fulfilling Amsterdam Criteria without Involvement of the Mutator Pathway Clinical Cancer Research 2005, 11: 7304-7310. PMID: 16243801, DOI: 10.1158/1078-0432.ccr-05-0965.
  • Accuracy of Revised Bethesda Guidelines, Microsatellite Instability, and Immunohistochemistry for the Identification of Patients With Hereditary Nonpolyposis Colorectal CancerPiñol V, Castells A, Andreu M, Castellví-Bel S, Alenda C, Llor X, Xicola RM, Rodríguez-Moranta F, Payá A, Jover R, Bessa X, Association F. Accuracy of Revised Bethesda Guidelines, Microsatellite Instability, and Immunohistochemistry for the Identification of Patients With Hereditary Nonpolyposis Colorectal Cancer JAMA 2005, 293: 1986-1994. PMID: 15855432, DOI: 10.1001/jama.293.16.1986.
  • "New Familial Colorectal Cancer Forms"Latest gastroenterology advances. Gastroenterol Hepatol. 2005; 3(1):54-58. Latest gastroenterology advances. Gastroenterol Hepatol. 2005; 3(1):54-58. Latest gastroenterology advances. Gastroenterol Hepatol. 2005; 3(1):54-58. Latest Gastroenterology Advances. Gastroenterol Hepatol. 2005; 3(1):54-58
  • The effects of fish oil, olive oil, oleic acid and linoleic acid on colorectal neoplastic processesLLOR X, PONS E, ROCA A, ÀLVAREZ M, MAÑÉ J, FERNÁNDEZ-BAÑARES F, GASSULL MA. The effects of fish oil, olive oil, oleic acid and linoleic acid on colorectal neoplastic processes Clinical Nutrition 2003, 22: 71-79. PMID: 12553953, DOI: 10.1054/clnu.2002.0627.
  • Papel de los lípidos de la dieta en los mecanismos de inflamación, proliferación, diferenciación y muerte celular en el tracto intestinalLlor X. Papel de los lípidos de la dieta en los mecanismos de inflamación, proliferación, diferenciación y muerte celular en el tracto intestinal Gastroenterología Y Hepatología 2003, 26: 507-513. PMID: 14534023, DOI: 10.1016/s0210-5705(03)70402-6.
  • Olive oil induces apoptosis and cell differentiation in Caco-2 cellsLlor X, Pons E, Alvarez M, Fernandez-Banares F, Gassull M. Olive oil induces apoptosis and cell differentiation in Caco-2 cells Gastroenterology 2000, 118: a536-a537. DOI: 10.1016/s0016-5085(00)84276-6.
  • BRK/Sik expression in the gastrointestinal tract and in colon tumors.Llor X, Serfas MS, Bie W, Vasioukhin V, Polonskaia M, Derry J, Abbott CM, Tyner AL. BRK/Sik expression in the gastrointestinal tract and in colon tumors. Clinical Cancer Research 1999, 5: 1767-77. PMID: 10430081.
  • "Characterization of the novel breast tumor kinase Brk"Book chapter. Breast Cancer Research Program. Department of Defense, USA. Era of Hope. Vol II. 1997; 2:121-127
  • "Expression of Tyrosine Kinases in the Mouse Small Intestine"Proceedings on Regulation of Cell Growth, Differentiation and Genetics in Cancer, pp. 308-318
  • Expression of Tyrosine Kinases in the Mouse Small IntestineTyner A, Vasioukhin V, Serfas M, Siyanova E, Llor X. Expression of Tyrosine Kinases in the Mouse Small Intestine 1996, 309-318. DOI: 10.1007/978-3-642-61180-3_28.
  • Tissue and cell-specific patterns of expression of rat liver and intestinal fatty acid binding protein during development and in experimental colonic and small intestinal adenocarcinomas.Davidson NO, Ifkovits CA, Skarosi SF, Hausman AM, Llor X, Sitrin MD, Montag A, Brasitus TA. Tissue and cell-specific patterns of expression of rat liver and intestinal fatty acid binding protein during development and in experimental colonic and small intestinal adenocarcinomas. Laboratory Investigation; A Journal Of Technical Methods And Pathology 1993, 68: 663-75. PMID: 8515653.
  • K-ras mutations in 1,2-dimethylhydrazine-induced colonic tumors: effects of supplemental dietary calcium and vitamin D deficiency.Llor X, Jacoby RF, Teng BB, Davidson NO, Sitrin MD, Brasitus TA. K-ras mutations in 1,2-dimethylhydrazine-induced colonic tumors: effects of supplemental dietary calcium and vitamin D deficiency. Cancer Research 1991, 51: 4305-9. PMID: 1868452.
  • Mutations in the K-ras oncogene induced by 1,2-dimethylhydrazine in preneoplastic and neoplastic rat colonic mucosa.Jacoby RF, Llor X, Teng BB, Davidson NO, Brasitus TA. Mutations in the K-ras oncogene induced by 1,2-dimethylhydrazine in preneoplastic and neoplastic rat colonic mucosa. The Journal Of Clinical Investigation 1991, 87: 624-30. PMID: 1991846, PMCID: PMC296352, DOI: 10.1172/JCI115039.
  • Effect of polyamine oxidase inhibition on the colonic malignant transformation process induced by 1,2-dimethylhydrazine.Halline AG, Dudeja PK, Jacoby RF, Llor X, Teng BB, Chowdhury LN, Davidson NO, Brasitus TA. Effect of polyamine oxidase inhibition on the colonic malignant transformation process induced by 1,2-dimethylhydrazine. Carcinogenesis 1990, 11: 2127-32. PMID: 2265465, DOI: 10.1093/carcin/11.12.2127.

Clinical Trials

ConditionsStudy Title
Diseases of the Digestive System - Small Intestines, Large Intestines & RectumBlood and Stool Sample Collection in Subjects with a Diagnosis of Colorectal Cancer or Colorectal Lesion 2018-07 Act Fast
Diseases of the Digestive System - Small Intestines, Large Intestines & RectumEvaluation of the ctDNA LUNAR Test in an Average Patient Screening Episode (ECLIPSE)
Edit Profile